<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1130" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1130/" /><meta name="ncbi_pagename" content="Arylsulfatase A Deficiency - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Arylsulfatase A Deficiency - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Arylsulfatase A Deficiency" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2017/12/14" /><meta name="citation_author" content="Natalia Gomez-Ospina" /><meta name="citation_pmid" content="20301309" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1130/" /><meta name="citation_keywords" content="ARSA Deficiency" /><meta name="citation_keywords" content="Metachromatic Leukodystrophy" /><meta name="citation_keywords" content="Metachromatic Leukodystrophy" /><meta name="citation_keywords" content="ARSA Deficiency" /><meta name="citation_keywords" content="Arylsulfatase A" /><meta name="citation_keywords" content="ARSA" /><meta name="citation_keywords" content="Arylsulfatase A Deficiency" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Arylsulfatase A Deficiency" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Natalia Gomez-Ospina" /><meta name="DC.Date" content="2017/12/14" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1130/" /><meta name="description" content="Arylsulfatase A deficiency (also known as metachromatic leukodystrophy or MLD) is characterized by three clinical subtypes: late-infantile MLD, juvenile MLD, and adult MLD. Age of onset within a family is usually similar. The disease course may be from several years in the late-infantile-onset form to decades in the juvenile- and adult-onset forms." /><meta name="og:title" content="Arylsulfatase A Deficiency" /><meta name="og:type" content="book" /><meta name="og:description" content="Arylsulfatase A deficiency (also known as metachromatic leukodystrophy or MLD) is characterized by three clinical subtypes: late-infantile MLD, juvenile MLD, and adult MLD. Age of onset within a family is usually similar. The disease course may be from several years in the late-infantile-onset form to decades in the juvenile- and adult-onset forms." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1130/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/mld/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1130/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8A3D94E0402D110000000003E60157.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1130_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1130_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/arts/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/as-def/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1130_"><span class="title" itemprop="name">Arylsulfatase A Deficiency</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonyms: ARSA Deficiency, Metachromatic Leukodystrophy</div><p class="contrib-group"><span itemprop="author">Natalia Gomez-Ospina</span>, MD, PhD.</p><a data-jig="ncbitoggler" href="#__NBK1130_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1130_ai__"><div class="contrib half_rhythm"><span itemprop="author">Natalia Gomez-Ospina</span>, MD, PhD<div class="affiliation small">Clinical Instructor, Medical Genetics<br />Pediatric Translational Medicine<br />Stanford University<br />Palo Alto, California<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.drofnats@psozemog" class="oemail">ude.drofnats@psozemog</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">May 30, 2006</span>; Last Update: <span itemprop="dateModified">December 14, 2017</span>.</p><p><em>Estimated reading time: 35 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="mld.Summary" itemprop="description"><h2 id="_mld_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Arylsulfatase A deficiency (also known as metachromatic leukodystrophy or MLD) is characterized by three clinical subtypes: late-infantile MLD, juvenile MLD, and adult MLD. Age of onset within a family is usually similar. The disease course may be from several years in the late-infantile-onset form to decades in the juvenile- and adult-onset forms.</p><p><i>Late-infantile MLD.</i> Onset is before age 30 months. Typical presenting findings include weakness, hypotonia, clumsiness, frequent falls, toe walking, and dysarthria. As the disease progresses, language, cognitive, and gross and fine motor skills regress. Later signs include spasticity, pain, seizures, and compromised vision and hearing. In the final stages, children have tonic spasms, decerebrate posturing, and general unawareness of their surroundings.</p><p><i>Juvenile MLD.</i> Onset is between age 30 months and 16 years. Initial manifestations include decline in school performance and emergence of behavioral problems, followed by gait disturbances. Progression is similar to but slower than in the late-infantile form.</p><p><i>Adult MLD.</i> Onset occurs after age 16 years, sometimes not until the fourth or fifth decade. Initial signs can include problems in school or job performance, personality changes, emotional lability, or psychosis; in others, neurologic symptoms (weakness and loss of coordination progressing to spasticity and incontinence) or seizures initially predominate. Peripheral neuropathy is common. Disease course is variable &#x02013; with periods of stability interspersed with periods of decline &#x02013; and may extend over two to three decades. The final stage is similar to earlier-onset forms.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of MLD is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with progressive neurologic dysfunction, MRI evidence of leukodystrophy, or ARSA enzyme deficiency and identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>ARSA</i> pathogenic variants on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>, or identification of elevated urinary excretion of sulfatides, or less commonly, identification of metachromatic lipid deposits in nervous system tissue.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Physical therapy and an enriched environment to maximize intellect, neuromuscular function, and mobility; family support to enable parents and/or caregivers to anticipate decisions on walking aids, wheelchairs, feeding tubes, and other changing care needs; treatment of seizures using antiepileptic drugs in standard protocols; treatment of contractures with muscle relaxants. Standard treatments for gastroesophageal reflux, constipation, drooling, dental care, pulmonary function, and impaired vison.</p><p><i>Prevention of primary manifestations:</i> Hematopoietic stem cell transplantation (HSCT) is the only therapy for primary central nervous system manifestations. Outcomes depend on the clinical stage and the presence of neurologic symptoms. The best results are observed when HSCT is performed in pre- and very early symptomatic individuals with the juvenile or adult form of the disease. HSCT is not recommended for individuals with symptomatic, late-infantile MLD.</p><p><i>Prevention of secondary complications:</i> Therapies designed to prevent decline in mobility, cognitive ability, communication, or food intake; safety measures for movement limitations and seizure precautions.</p><p><i>Surveillance:</i> Regular monitoring by a neurologist or metabolic geneticist including evaluation for changes in motor function, development of seizures, contractions, feeding difficulties, and disease progression following anesthesia or fever; periodic brain MRI examination.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>MLD is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier. Carrier testing of at-risk family members and prenatal testing for a pregnancy at increased risk are possible if both <i>ARSA</i> pathogenic variants have been identified in an affected family member.</p></div></div><div id="mld.Diagnosis"><h2 id="_mld_Diagnosis_">Diagnosis</h2><div id="mld.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Arylsulfatase A deficiency (also known as metachromatic leukodystrophy or MLD) <b>should be suspected</b> in individuals with the following:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Progressive neurologic dysfunction.</b> Presenting signs may be behavioral or motor. Symptoms can occur at any age beyond one year and follow a period of normal development.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>MRI evidence of a leukodystrophy.</b> Diffuse symmetric abnormalities of periventricular myelin with hyperintensities on T<sub>2</sub>-weighted images. Initial parieto-occipital preponderance is observed in most individuals with late-infantile MLD, with subcortical U-fibers and cerebellar white matter spared. The abnormal white matter is often described as having a tigroid pattern or radial stripes. As the disease progresses, MRI abnormalities become more pronounced in a rostral-to-caudal progression and cerebral atrophy develops [<a class="bk_pop" href="#mld.REF.groeschel.2011.1095">Groeschel et al 2011</a>]. Anterior lesions may be more common initially in individuals with later onset. Not all persons with MLD show white matter lesions initially. Isolated cranial nerve enhancement preceding intraparenchymal white matter involvement has been reported [<a class="bk_pop" href="#mld.REF.morana.2009.291">Morana et al 2009</a>, <a class="bk_pop" href="#mld.REF.singh.2009.380">Singh et al 2009</a>].</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Arylsulfatase A (ARSA) enzyme deficiency.</b> ARSA activity in leukocytes that is less than 10% of normal controls using the usual synthetic-substrate-based assay. Decreased ARSA activity is not sufficient for the diagnosis of MLD, as it may reflect ARSA pseudodeficiency.</div><div class="half_rhythm">Note: (1) The use of low-temperature assays can minimize interference by other arylsulfatases and lower the baseline level [<a class="bk_pop" href="#mld.REF.rip.1998.29">Rip &#x00026; Gordon 1998</a>]. (2) Cultured skin fibroblasts have often been used to confirm deficiency of ARSA enzyme activity and to evaluate the capacity of intact cells for sulfatide breakdown (sulfatide loading test). Such testing is usually not necessary for establishing the diagnosis but can be useful when the diagnosis is ambiguous (pseudodeficiency vs late-onset MLD) or is being made presymptomatically. (3) Enzyme activity and sulfatide loading can be performed in cultured amniocytes or CVS cells for prenatal diagnoses; see Genetic Counseling, <a href="#mld.Prenatal_Testing_and_Preimplantation">Prenatal Testing and Preimplantation Genetic Diagnosis</a>.</div></li></ul><p><b>ARSA enzyme pseudodeficiency.</b> Pseudodeficiency is suggested by ARSA enzyme activity in leukocytes that is 5% to 20% of normal controls. Pseudodeficiency is difficult to distinguish from true ARSA enzyme deficiency by biochemical testing alone.</p><p>Note: For MLD the term "pseudodeficiency" refers to very low levels of ARSA enzyme activity in an otherwise healthy individual. The term has been applied to other enzyme deficiency disorders, such as <a href="/books/n/gene/tay-sachs/">hexosaminidase A deficiency</a>, where specific variants are associated with reduced enzymatic activity when measured using synthetic substrate but have normal enzymatic activity when measured using a natural substrate.</p><p><b>Newborn screening</b> for MLD based on enzyme activity has been difficult due to the high occurrence of ARSA enzyme pseudodeficiency and the inability to distinguish MLD from pseudodeficiency. A mass spectrometry-based method to quantify sulfatides in dried blood and urine spots has been developed [<a class="bk_pop" href="#mld.REF.spacil.2016.279">Spacil et al 2016</a>] and a large-scale pilot study for <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> to evaluate this method for sulfatide analysis in dried blood spots has begun at the University of Washington, Seattle.</p></div><div id="mld.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of arylsulfatase A deficiency (metachromatic leukodystrophy, MLD) <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> by the presence of suggestive findings (e.g., progressive neurologic dysfunction, MRI evidence of leukodystrophy, or ARSA enzyme deficiency) and ANY of the following:</p><ul><li class="half_rhythm"><div>Identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>ARSA</i> pathogenic variants on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK1130/table/mld.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figmldTmoleculargenetictestingusedin" rid-ob="figobmldTmoleculargenetictestingusedin">Table 1</a>)</div></li><li class="half_rhythm"><div>Identification of increased urinary excretion of sulfatides</div></li><li class="half_rhythm"><div>Identification of metachromatic lipid deposits in a nerve or brain biopsy</div></li></ul><div id="mld.Molecular_Genetic_Testing"><h4>Molecular Genetic Testing</h4><p>Three classes of <i>ARSA</i> alleles resulting in low ARSA enzyme activity need to be distinguished (see <a href="#mld.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</a>):</p><ul><li class="half_rhythm"><div><i>ARSA</i> pathogenic variants that cause MLD (<i>ARSA</i>-MLD alleles) in the <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> or <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> state</div></li><li class="half_rhythm"><div><i>ARSA</i> alleles with sequence variants resulting in pseudodeficiency (<i>ARSA-</i>PD)</div></li><li class="half_rhythm"><div>Alleles with two <i>ARSA</i> sequence variants on the same <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> (<a class="def" href="/books/n/gene/glossary/def-item/cis/"><i>cis</i></a> configuration). For example, individuals can have <i>ARSA</i>-MLD and <i>ARSA-</i>PD alleles <i>in</i>
<i>cis</i>.</div></li></ul><p>Molecular genetic testing approaches can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b>, use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>, and <b>more comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b>. Parental testing may be necessary to determine the phase of the identified variants in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis of <i>ARSA</i> is performed first and followed by gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> if only one or no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Use of a <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>ARSA</i> and other genes of interest (see <a href="#mld.Differential_Diagnosis">Differential Diagnosis</a>) can be considered. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>More comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (when available) including <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a> and <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a> may be considered. Such testing may provide or suggest a diagnosis not previously considered (e.g., mutation of a different <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> or genes that results in a similar clinical presentation).</div><div class="half_rhythm">For an introduction to comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</div></li></ul><div id="mld.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Arylsulfatase A Deficiency</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1130/table/mld.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__mld.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_mld.T.molecular_genetic_testing_used_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_mld.T.molecular_genetic_testing_used_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Test Method</th><th id="hd_h_mld.T.molecular_genetic_testing_used_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by This Method</th></tr></thead><tbody><tr><td headers="hd_h_mld.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>ARSA</i></td><td headers="hd_h_mld.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_mld.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">90%-95%&#x000a0;<sup>4, 5, 6</sup></td></tr><tr><td headers="hd_h_mld.T.molecular_genetic_testing_used_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>7</sup></td><td headers="hd_h_mld.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;1%&#x000a0;<sup>8</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="mld.TF.1.1"><p class="no_margin">See <a href="/books/NBK1130/#mld.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="mld.TF.1.2"><p class="no_margin">See <a href="#mld.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="mld.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="mld.TF.1.4"><p class="no_margin">Four pathogenic variants (<a class="figpopup" href="/books/NBK1130/table/mld.T.selected_arsa_variants/?report=objectonly" target="object" rid-figpopup="figmldTselectedarsavariants" rid-ob="figobmldTselectedarsavariants">c.459+1G&#x0003e;A</a>, <a class="figpopup" href="/books/NBK1130/table/mld.T.selected_arsa_variants/?report=objectonly" target="object" rid-figpopup="figmldTselectedarsavariants" rid-ob="figobmldTselectedarsavariants">c.1204+1G&#x0003e;A</a>, <a class="figpopup" href="/books/NBK1130/table/mld.T.selected_arsa_variants/?report=objectonly" target="object" rid-figpopup="figmldTselectedarsavariants" rid-ob="figobmldTselectedarsavariants">p.Pro426Leu</a>, and <a class="figpopup" href="/books/NBK1130/table/mld.T.selected_arsa_variants/?report=objectonly" target="object" rid-figpopup="figmldTselectedarsavariants" rid-ob="figobmldTselectedarsavariants">p.Ile179Ser</a>) account for 25%-50% of the <i>ARSA</i> pathogenic variants in individuals of central and western European ancestry (see <a class="figpopup" href="/books/NBK1130/table/mld.T.distribution_of_the_most_common_ar/?report=objectonly" target="object" rid-figpopup="figmldTdistributionofthemostcommonar" rid-ob="figobmldTdistributionofthemostcommonar">Table 4</a>).</p></div></dd><dt>5. </dt><dd><div id="mld.TF.1.5"><p class="no_margin">Using scanning for pathogenic variants, <a class="bk_pop" href="#mld.REF.gort.1999.240">Gort et al [1999]</a> identified all of the <i>ARSA</i> pathogenic variants in 18 unrelated <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> persons of Spanish heritage.</p></div></dd><dt>6. </dt><dd><div id="mld.TF.1.6"><p class="no_margin">This test method also detects the <i>ARSA</i> pseudodeficiency alleles (termed <i>ARSA</i>-PD), common variants that result in lower-than-average ARSA enzyme activity but <b>do not cause MLD</b> either in the <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> state or in the <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> state with an <i>ARSA</i>-MLD <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>.</p></div></dd><dt>7. </dt><dd><div id="mld.TF.1.7"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>8. </dt><dd><div id="mld.TF.1.8"><p class="no_margin">Complete <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of <i>ARSA</i> associated with MLD has been reported [<a class="bk_pop" href="#mld.REF.coultermackie.1995.787">Coulter-Mackie et al 1995</a>, <a class="bk_pop" href="#mld.REF.eng.2004.95">Eng et al 2004</a>, <a class="bk_pop" href="#mld.REF.bisgaard.2009.175">Bisgaard et al 2009</a><u>]</u>. No instances of whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> are known. Dispermic chimeris, in which two copies of <i>ARSA</i> were transmitted by the father, has been reported [<a class="bk_pop" href="#mld.REF.coultermackie.2001.e15">Coulter-Mackie et al 2001</a>].</p></div></dd></dl></div></div></div></div><div id="mld.Urinary_Sulfatides"><h4>Urinary Sulfatides</h4><p>All types of MLD excrete abnormally high sulfatides in urine. These can be quantified by high-performance liquid chromatography (HPLC), mass spectrometry, and thin-layer chromatography (TLC). TLC is a semi-quantitative method. For HPCL and mass spectrometry, reference and pathologic values vary by laboratory. Because urine production is highly variable, sulfatide excretion is measured in a 24-hour urine sample or normalized to the urinary excretion of creatinine. <i>ARSA</i>-PD/<i>ARSA</i>-MLD compound heterozygotes can excrete higher-than-normal amounts of sulfatides but urinary sulfatide excretion is not as elevated as in individuals with MLD (usually &#x0003e;10x normal).</p><p>Note: Elevated urine sulfatides and ARSA enzyme deficiency in the presence of <a class="def" href="/books/n/gene/glossary/def-item/dysmorphic/">dysmorphic</a> features, dysostosis multiplex, or ichthyosis should prompt evaluation for multiple sulfatase deficiency (see <a href="#mld.Differential_Diagnosis">Differential Diagnosis</a>).</p></div><div id="mld.Metachromatic_Lipid_Deposits_in_a_Ne"><h4>Metachromatic Lipid Deposits in a Nerve or Brain Biopsy</h4><p>Sulfatides interact strongly with certain positively charged dyes used to stain tissues, resulting in a shift in the color of the stained tissue termed <b>metachromasia</b>. When frozen tissue sections are treated with acidified cresyl violet (Hirsch-Peiffer stain), sulfatide-rich storage deposits stain a golden brown. The finding of metachromatic lipid deposits in nervous system tissue is pathognomonic for MLD.</p><p>Note: (1) Fixing the tissue with alcohol before staining extracts the sulfatides such that the metachromasia is no longer observed. (2) Although still considered by some to be the diagnostic "gold standard" for MLD, this highly invasive approach is now used only in exceptional circumstances (e.g., confirmation of a <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> of MLD following pregnancy termination).</p></div></div></div><div id="mld.Clinical_Characteristics"><h2 id="_mld_Clinical_Characteristics_">Clinical Characteristics</h2><div id="mld.Clinical_Description"><h3>Clinical Description</h3><p>The clinical presentation of arylsulfatase A deficiency (metachromatic leukodystrophy, MLD) is heterogeneous with respect to the age of onset, the rate of progression, and the initial symptoms. Three clinical subtypes of MLD are primarily distinguished by age of onset:</p><ul><li class="half_rhythm"><div>Late-infantile MLD, comprising 50%-60% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals</div></li><li class="half_rhythm"><div>Juvenile MLD, approximately 20%-30%</div></li><li class="half_rhythm"><div>Adult MLD, approximately 15%-20%</div></li></ul><p>The age of onset within a family is usually similar, but exceptions occur [<a class="bk_pop" href="#mld.REF.arbour.2000.173">Arbour et al 2000</a>]. Although the presenting symptoms and age of onset vary, all individuals eventually develop complete loss of motor, sensory, and intellectual functions. The disease course may be from several years in the late-infantile-onset form to decades in the juvenile- and adult-onset forms [<a class="bk_pop" href="#mld.REF.von_figura.2001">Von Figura et al 2001</a>]. Death most commonly results from pneumonia or other infection. Life span correlates roughly with the age of onset but can be quite variable, particularly in the later-onset forms.</p><p><b>Late-infantile MLD.</b> Age of onset is before age 30 months, following a period of apparently normal development. In the initial stage, weakness, hypotonia, and depressed deep tendon reflexes are observed. Clumsiness, frequent falls, toe walking, and dysarthria are other typical presenting signs. Symptoms may first be noted following anesthesia or a febrile illness and may subside for weeks before continuing to progress. Less commonly, seizures are the first neurologic sign. Out of 38 individuals reported with late-infantile MLD, 61% presented with motor or gait abnormalities and 39% of individuals presented with seizures [<a class="bk_pop" href="#mld.REF.mahmood.2010.572">Mahmood et al 2010</a>]. Seventy-five percent of individuals show first motor symptoms before age 18 months [<a class="bk_pop" href="#mld.REF.kehrer.2011a.850">Kehrer et al 2011a</a>]. Peripheral neuropathy with slow nerve conduction velocities (NCVs) is common. Brain auditory and visual evoked response testing demonstrate impairment in hearing and vision.</p><p>As the disease progresses, language, cognitive development, and gross- and fine-motor skills regress. Peripheral neuropathy can lead to pain in the arms and legs. In one study, individuals with the late-infantile form had lost the ability to sit without support and to move by age three years, and all had lost both trunk and head control by age three years four months [<a class="bk_pop" href="#mld.REF.kehrer.2011a.850">Kehrer et al 2011a</a>]. Eventually spasticity becomes prominent and bulbar involvement can result in airway obstruction and feeding difficulties requiring gastrostomy tube placement. Generalized or partial seizures can occur and vision and hearing become progressively compromised. Eventually, the child becomes bedridden with tonic spasms, decerebrate posturing, and general unawareness. Most children die within five years after the onset of symptoms, although survival can extend into the second decade of life with current levels of care.</p><p><b>Juvenile MLD.</b> Age of onset is between ages 30 months and 16 years with a median age of six years two months [<a class="bk_pop" href="#mld.REF.kehrer.2011a.850">Kehrer et al 2011a</a>]. Symptoms start insidiously with a decline in school performance, abnormal behaviors, or psychiatric symptoms. In published reports of individuals with juvenile MLD, 66% presented with inattention and difficulties at school, 26% with gait difficulties, 18% with tremor or ataxia, 13% with neuropathy, and 5% with seizures [<a class="bk_pop" href="#mld.REF.mahmood.2010.572">Mahmood et al 2010</a>]. Early- and late-juvenile subvariants are sometimes differentiated, neuromuscular difficulties developing first in individuals with earlier-onset MLD and behavioral issues developing first in individuals with later-onset MLD.</p><p>Progression is similar to but slower than in the late-infantile form. The rate of motor deterioration can be quite variable [<a class="bk_pop" href="#mld.REF.kehrer.2011a.850">Kehrer et al 2011a</a>]. The majority of individuals die before age 20 years, but survival is quite variable.</p><p><b>Adult MLD.</b> Symptoms are first noted after sexual maturity (age ~16 years) but may not occur until the fourth or fifth decade. As with juvenile MLD, presenting symptoms vary. Initial signs are often emerging problems in school or job performance. Alcohol or drug use, poor money management, emotional lability, inappropriate affect, and frank psychosis often lead to psychiatric evaluation and an initial diagnosis of dementia, schizophrenia, or depression. In others, neurologic symptoms (weakness and loss of coordination progressing to spasticity and incontinence) predominate initially, leading to diagnosis of multiple sclerosis or other neurodegenerative diseases. Among published cases of adult MLD, 72% presented with dementia and behavioral difficulties, 16% with psychosis and schizophrenia, 28% with neuropathy, and 12% with seizures [<a class="bk_pop" href="#mld.REF.mahmood.2010.572">Mahmood et al 2010</a>]. Peripheral neuropathy, though a frequent aspect of adult-onset MLD, is not present in all individuals.</p><p>The course is variable. Periods of relative stability may be interspersed with periods of decline. Inappropriate behaviors and poor decision making become problems for the family or other caregivers. Dressing and other self-help skills deteriorate. Eventually, bowel and bladder control is lost. As the disease advances, dystonic movements, spastic quadriparesis, or decorticate posturing occurs. Severe contractures and generalized seizures may occur. The duration of the disease ranges from several years to decades.</p><p><b>Other findings in MLD</b></p><ul><li class="half_rhythm"><div>In the past, findings of increased concentration of cerebrospinal fluid protein, decreased NCVs, and abnormal auditory and visual evoked potential studies were used in diagnosis. While such tests are no longer necessary for diagnosis, they may be used in protocols for monitoring disease progression or therapeutic trials. Notably, nerve conduction abnormalities, which are almost universal in individuals with MLD, can be present before clinical symptoms appear.</div></li><li class="half_rhythm"><div>Outside the central nervous system, sulfatide accumulation has been found in other organs. In the gallbladder, hyperplastic polyps are common and hemobilia as well as gallbladder carcinoma have been reported as complications [<a class="bk_pop" href="#mld.REF.garavelli.2009.284">Garavelli et al 2009</a>, <a class="bk_pop" href="#mld.REF.van_rappard.2016b.103">van Rappard et al 2016b</a>]. Polypoid masses in stomach and duodenum complicated by intestinal intussusception have also been reported [<a class="bk_pop" href="#mld.REF.yavuz.2011.117">Yavuz &#x00026; Yuksekkaya 2011</a>].</div></li></ul><p><b>Pathogenesis.</b> Arylsulfatase A deficiency is a disorder of impaired breakdown of sulfatides (cerebroside sulfate or 3-0-sulfo-galactosylceramide), sulfate-containing lipids that occur throughout the body and are found in greatest abundance in nervous tissue, kidneys, and testes. Sulfatides are critical constituents in the nervous system, where they comprise approximately 5% of the myelin lipids. Sulfatide accumulation in the nervous system eventually leads to myelin breakdown (leukodystrophy) and a progressive neurologic disorder [<a class="bk_pop" href="#mld.REF.von_figura.2001">Von Figura et al 2001</a>].</p></div><div id="mld.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p><b>ARSA enzyme activity</b></p><ul><li class="half_rhythm"><div>The genotypes <i>ARSA</i>-MLD/<i>ARSA</i>-MLD, <i>ARSA</i>-PD-MLD/<i>ARSA</i>-MLD, and <i>ARSA</i>-PD-MLD/<i>ARSA</i>-PD-MLD result in ARSA enzyme activity that is 0%-10% of control values in synthetic-substrate-based assays.</div></li><li class="half_rhythm"><div>The <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> <i>ARSA</i>-PD/<i>ARSA</i>-MLD usually results in ARSA enzyme activity that is approximately 10% of control values, while the genotype <i>ARSA</i>-PD/<i>ARSA</i>-PD results in ARSA enzyme activity that is approximately 10%-20% of control values.</div></li></ul><p><b>Age of onset of MLD</b></p><ul><li class="half_rhythm"><div><b>Early-onset (late-infantile) MLD.</b> Affected individuals are usually <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> or <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> for <i>ARSA</i>-MLD alleles that make no detectable functional arylsulfatase A enzyme (I-type or <a class="def" href="/books/n/gene/glossary/def-item/null/">null</a> alleles) [<a class="bk_pop" href="#mld.REF.cesani.2009.e936">Cesani et al 2009</a>]. The most common I-type alleles are <a class="figpopup" href="/books/NBK1130/table/mld.T.selected_arsa_variants/?report=objectonly" target="object" rid-figpopup="figmldTselectedarsavariants" rid-ob="figobmldTselectedarsavariants">c.459+1G&#x0003e;A</a>, <a class="figpopup" href="/books/NBK1130/table/mld.T.selected_arsa_variants/?report=objectonly" target="object" rid-figpopup="figmldTselectedarsavariants" rid-ob="figobmldTselectedarsavariants">c.1204+1G&#x0003e;A</a>, and <a class="figpopup" href="/books/NBK1130/table/mld.T.selected_arsa_variants/?report=objectonly" target="object" rid-figpopup="figmldTselectedarsavariants" rid-ob="figobmldTselectedarsavariants">p.Asp255His</a>.</div></li><li class="half_rhythm"><div><b>Later-onset MLDs.</b> Affected individuals have one or two <i>ARSA</i>-MLD alleles that encode for an arylsulfatase A enzyme with some residual functional activity (&#x02264;1% when assayed with physiologic substrates) known as R-type alleles. The most common R-type <i>ARSA</i>-MLD alleles are <a class="figpopup" href="/books/NBK1130/table/mld.T.selected_arsa_variants/?report=objectonly" target="object" rid-figpopup="figmldTselectedarsavariants" rid-ob="figobmldTselectedarsavariants">p.Ile179Ser</a> and <a class="figpopup" href="/books/NBK1130/table/mld.T.selected_arsa_variants/?report=objectonly" target="object" rid-figpopup="figmldTselectedarsavariants" rid-ob="figobmldTselectedarsavariants">p.Pro426Leu</a> [<a class="bk_pop" href="#mld.REF.fluharty.1991.1340">Fluharty et al 1991</a>]:</div><ul><li class="half_rhythm"><div><b>Juvenile-onset MLD.</b> Often these individuals are <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> for an I-type and an R-type <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>.</div></li><li class="half_rhythm"><div><b>Adult-onset MLD.</b> Both alleles provide some residual enzyme activity (R-type <i>ARSA</i>-MLD alleles).</div></li></ul></li></ul><p><b>Adult MLD subtypes</b></p><ul><li class="half_rhythm"><div><b>Neurologic type.</b> Affected individuals are usually <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for the <a class="figpopup" href="/books/NBK1130/table/mld.T.selected_arsa_variants/?report=objectonly" target="object" rid-figpopup="figmldTselectedarsavariants" rid-ob="figobmldTselectedarsavariants">p.Pro426Leu</a> R-type <i>ARSA</i>-MLD <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> [<a class="bk_pop" href="#mld.REF.rauschka.2006.859">Rauschka et al 2006</a>].</div></li><li class="half_rhythm"><div><b>Psychiatric type.</b> Affected individuals are usually <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> for the <a class="figpopup" href="/books/NBK1130/table/mld.T.selected_arsa_variants/?report=objectonly" target="object" rid-figpopup="figmldTselectedarsavariants" rid-ob="figobmldTselectedarsavariants">p.Ile179Ser</a> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> and any other R-type <i>ARSA</i>-MLD allele [<a class="bk_pop" href="#mld.REF.rauschka.2006.859">Rauschka et al 2006</a>].</div></li></ul><p>There are substantial limitations to the use of these <a class="def" href="/books/n/gene/glossary/def-item/genotype-phenotype-correlations/">genotype-phenotype correlations</a> in predicting the clinical presentation and natural history of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual. The predictive value is best for individuals <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for two I-type alleles, but individuals with one or two R-type alleles show considerable phenotypic variability, implicating other genetic and/or environmental factors [<a class="bk_pop" href="#mld.REF.wang.2011">Wang et al 2011</a>]. Notably, additional variants in the same <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> can further affect enzyme function and disease severity [<a class="bk_pop" href="#mld.REF.regis.2002.351">Regis et al 2002</a>].</p><p><b>Arylsulfatase A (ARSA) pseudodeficiency</b></p><ul><li class="half_rhythm"><div><b><i>ARSA</i>-MLD/<i>ARSA</i>-PD <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a>.</b> Associated ARSA enzyme activity is 5% to 10% of normal controls:</div><ul><li class="half_rhythm"><div>The polyadenylation site <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, <a class="figpopup" href="/books/NBK1130/table/mld.T.selected_arsa_variants/?report=objectonly" target="object" rid-figpopup="figmldTselectedarsavariants" rid-ob="figobmldTselectedarsavariants">c.*96A&#x0003e;G</a>, appears to contribute most strongly to the low ARSA enzyme activity characteristic of clinical pseudodeficiency [<a class="bk_pop" href="#mld.REF.harvey.1998.1215">Harvey et al 1998</a>].</div></li><li class="half_rhythm"><div><a class="figpopup" href="/books/NBK1130/table/mld.T.selected_arsa_variants/?report=objectonly" target="object" rid-figpopup="figmldTselectedarsavariants" rid-ob="figobmldTselectedarsavariants">p.Asn350Ser</a>, the glycosylation site alteration, is associated with an increased excretion of the newly synthesized enzyme from cells and a possible decrease in the ARSA enzyme within the lysosome [<a class="bk_pop" href="#mld.REF.harvey.1998.1215">Harvey et al 1998</a>].</div></li><li class="half_rhythm"><div>The most common <i>ARSA-</i>PD <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> in the European and American populations has these two sequence variants in <a class="def" href="/books/n/gene/glossary/def-item/cis/"><i>cis</i></a> configuration (i.e., on the same <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a>), designated as <a class="figpopup" href="/books/NBK1130/table/mld.T.selected_arsa_variants/?report=objectonly" target="object" rid-figpopup="figmldTselectedarsavariants" rid-ob="figobmldTselectedarsavariants">c.[1049A&#x0003e;G; *96A&#x0003e;G]</a>.</div></li></ul></li><li class="half_rhythm"><div><b><i>ARSA</i>-PD/<i>ARSA</i>-PD <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a></b></div><ul><li class="half_rhythm"><div>Homozygosity for the <a class="figpopup" href="/books/NBK1130/table/mld.T.selected_arsa_variants/?report=objectonly" target="object" rid-figpopup="figmldTselectedarsavariants" rid-ob="figobmldTselectedarsavariants">c.*96A&#x0003e;G</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> (almost always in conjunction with <a class="figpopup" href="/books/NBK1130/table/mld.T.selected_arsa_variants/?report=objectonly" target="object" rid-figpopup="figmldTselectedarsavariants" rid-ob="figobmldTselectedarsavariants">p.Asn350Ser</a>) is associated with ARSA enzyme activity that is approximately 10% of normal controls and could result in diagnostic uncertainty.</div></li><li class="half_rhythm"><div>Homozygosity for the <a class="figpopup" href="/books/NBK1130/table/mld.T.selected_arsa_variants/?report=objectonly" target="object" rid-figpopup="figmldTselectedarsavariants" rid-ob="figobmldTselectedarsavariants">p.Asn350Ser</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> alone results in 50% or more of the mean control ARSA enzyme activity in leukocytes.</div></li></ul></li></ul></div><div id="mld.Nomenclature"><h3>Nomenclature</h3><p>The term metachromatic leukodystrophy (<i>metachromatischen Leukodystrophien</i>) was first used by <a class="bk_pop" href="#mld.REF.peiffer.1959.386">Peiffer [1959]</a> to describe what had previously been known as "diffuse brain sclerosis."</p><p>The term "metachromatic leukoencephalopathy" has also been used.</p><p>MLD has also been referred to as "Greenfield's disease" after the first report of the late-infantile form of MLD.</p></div><div id="mld.Prevalence"><h3>Prevalence</h3><p><b>Arylsulfatase A deficiency.</b> The overall prevalence of arylsulfatase A deficiency has been reported at between 1:40,000 and 1:160,000 in different populations [<a class="bk_pop" href="#mld.REF.von_figura.2001">Von Figura et al 2001</a>]. Assuming the prevalence stated, the overall <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> frequency is between 1:100 and 1:200. The disorder is pan ethnic; however, most data come from European and North American populations. Males and females are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> equally and there is no difference in survival.</p><p>Based on their determination of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status for the most common <i>ARSA</i> pathogenic variants in two large (&#x0003e;~3000-person) samples of the Polish population, <a class="bk_pop" href="#mld.REF._ugowska.2011.e20218">&#x00141;ugowska et al [2011]</a> estimated the birth incidence at 4.1:100,000 live births. Comparing this to the incidence calculated from the number of individuals with MLD diagnosed from 1975 to 2004 (0.38:100,000), they suggest that metachromatic leukodystrophy may be substantially underdiagnosed in the Polish population.</p><p>In the following <a class="def" href="/books/n/gene/glossary/def-item/consanguineous/">consanguineous</a> populations, the disease prevalence can be much higher (figures are approximate):</p><ul><li class="half_rhythm"><div>1:75 in Habbanite Jews in Israel</div></li><li class="half_rhythm"><div>1:8,000 in Israeli Arabs</div></li><li class="half_rhythm"><div>1:2,500 in Eskimos</div></li><li class="half_rhythm"><div>1: 6,400 for the western portion of the Navajo Nation in the US</div></li></ul><p><b><i>ARSA</i>-PD alleles.</b> The <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> <i>ARSA</i>-PD <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> occurs in as many as 0.5%-2% of the European/Euro-American population and may be even more common in Asian and African populations. Thus, an <i>ARSA</i>-PD homozygous genotype is more than 400-fold more common than the <i>ARSA</i>-MLD homozygous genotype, and an <i>ARSA</i>-PD/<i>ARSA</i>-MLD <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> genotype is 30- to 50-fold more common than the <i>ARSA</i>-MLD homozygous genotype.</p><p>An <i>ARSA</i>-MLD variant is as likely to be found on an <i>ARSA</i>-PD <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> as on a wild type allele, implying that 0.5%-1% of <i>ARSA</i>-PD alleles are associated with a <a class="def" href="/books/n/gene/glossary/def-item/cis/"><i>cis</i></a>
<i>ARSA</i>-MLD variant (so-called <i>ARSA</i>-MLD-PD alleles).</p></div></div><div id="mld.Genetically_Related_Allelic_Disorder"><h2 id="_mld_Genetically_Related_Allelic_Disorder_">Genetically Related (Allelic) Disorders</h2><p>Individuals with the <a href="/books/n/gene/gr_22q13_3/">22q13.3 deletion syndrome</a> (Phelan-McDermid syndrome) often have a <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of <i>ARSA</i>. Presence of an <i>ARSA</i>-MLD or <i>ARSA</i>-PD <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> on the homologous <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> resulting in MLD and arylsulfatase A pseudodeficiency respectively has been reported in 22q13.3 <a class="def" href="/books/n/gene/glossary/def-item/deletion-syndrome/">deletion syndrome</a> [<a class="bk_pop" href="#mld.REF.bisgaard.2009.175">Bisgaard et al 2009</a>].</p></div><div id="mld.Differential_Diagnosis"><h2 id="_mld_Differential_Diagnosis_">Differential Diagnosis</h2><p><b>Arylsulfatase A deficiency.</b> The two phenotypes that show notable overlap with arylsulfatase A deficiency are multiple sulfatase deficiency and saposin B deficiency (<a class="figpopup" href="/books/NBK1130/table/mld.T.disorders_to_consider_in_the_diffe/?report=objectonly" target="object" rid-figpopup="figmldTdisorderstoconsiderinthediffe" rid-ob="figobmldTdisorderstoconsiderinthediffe">Table 2</a>).</p><div id="mld.T.disorders_to_consider_in_the_diffe" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Disorders to Consider in the Differential Diagnosis of Arylsulfatase A Deficiency</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1130/table/mld.T.disorders_to_consider_in_the_diffe/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__mld.T.disorders_to_consider_in_the_diffe_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_mld.T.disorders_to_consider_in_the_diffe_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Disorder</th><th id="hd_h_mld.T.disorders_to_consider_in_the_diffe_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Age at Onset</th><th id="hd_h_mld.T.disorders_to_consider_in_the_diffe_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Main Clinical Manifestations</th><th id="hd_h_mld.T.disorders_to_consider_in_the_diffe_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Urinary Excretion</th><th id="hd_h_mld.T.disorders_to_consider_in_the_diffe_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Enzyme Activity</th></tr></thead><tbody><tr><td headers="hd_h_mld.T.disorders_to_consider_in_the_diffe_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Multiple sulfatase deficiency<br />(OMIM <a href="http://omim.org/entry/272200" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">272200</a>)</td><td headers="hd_h_mld.T.disorders_to_consider_in_the_diffe_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1-4 years, probably variable</td><td headers="hd_h_mld.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">MLD-like clinical picture w/ elevated CSF protein &#x00026; slowed NCVs; MPS-like features, &#x00026; ichthyosis</td><td headers="hd_h_mld.T.disorders_to_consider_in_the_diffe_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Elevated sulfatide &#x00026; mucopolysaccharides</td><td headers="hd_h_mld.T.disorders_to_consider_in_the_diffe_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Very low ARSA enzyme activity; deficiency of most sulfatases in leukocytes or cultured cells&#x000a0;<sup>1</sup></td></tr><tr><td headers="hd_h_mld.T.disorders_to_consider_in_the_diffe_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Saposin B deficiency<br />(OMIM <a href="http://omim.org/entry/249900" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">249900</a>)</td><td headers="hd_h_mld.T.disorders_to_consider_in_the_diffe_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Variable</td><td headers="hd_h_mld.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">MLD-like clinical picture</td><td headers="hd_h_mld.T.disorders_to_consider_in_the_diffe_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Elevated sulfatide &#x00026; other glycolipids</td><td headers="hd_h_mld.T.disorders_to_consider_in_the_diffe_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">ARSA enzyme activity in normal range</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">CSF = cerebrospinal fluid; MPS = mucopolysaccharidosis; NCV = nerve conduction velocity</p></div></dd><dt>1. </dt><dd><div id="mld.TF.2.1"><p class="no_margin">Including arylsulfatase B, arylsulfatase C, galactose-6 sulfatase, glucuronate-2 sulfatase, iduronate sulfatase, heparan-N-sulfamidase, and N-acetylglucosamine-6 sulfatase.</p></div></dd></dl></div></div></div><p><b>Other ARSA deficiency conditions.</b> ARSA enzyme activity is also deficient in many tissues in defects of the phosphomannosyl lysosomal recognition pathway, such as I-cell disease (<a href="/books/n/gene/ml2/">mucolipidosis II</a>). The <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in I-cell disease is severe in infancy and is not likely to be confused with arylsulfatase A deficiency.</p><p><b>Other leukodystrophies and lysosomal storage diseases.</b> MLD is difficult to differentiate from other progressive degenerative disorders that manifest after a period of normal development. Delayed development in late infancy, coupled with loss of acquired abilities, should prompt MRI evaluation. If a generalized leukodystrophy is evident, other conditions to consider include: <a href="/books/n/gene/krabbe/">Krabbe disease</a>, <a href="/books/n/gene/x-ald/">X-linked adrenoleukodystrophy</a>, <a href="/books/n/gene/pmd/">Pelizaeus-Merzbacher disease</a>, <a href="/books/n/gene/alexander/">Alexander disease</a>, fucosidosis (OMIM <a href="http://omim.org/entry/230000" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">230000</a>), <a href="/books/n/gene/canavan/">Canavan disease</a>, and gangliosidoses such as <a href="/books/n/gene/tay-sachs/">hexosaminidase A deficiency</a> (including Tay-Sachs disease).</p><p>Although some mucopolysaccharidoses can have a similar presentation to arylsulfatase A deficiency, the characteristic physical features seen in most mucopolysaccharidoses (i.e., short stature, dysostosis multiplex, coarse facial appearance, corneal clouding, hepatosplenomegaly, pulmonary congestion, and heart problems) are not found in individuals with MLD. The evaluation of appropriate lysosomal enzymes can distinguish the disorders.</p><p><b>Arylsulfatase A pseudodeficiency.</b> Because of the high prevalence of the <i>ARSA</i>-PD alleles, low ARSA enzyme activity caused by arylsulfatase pseudodeficiency can be found in association with many disorders and can be erroneously implicated in individuals diagnosed with common psychiatric or neurologic disorders.</p></div><div id="mld.Management"><h2 id="_mld_Management_">Management</h2><div id="mld.Evaluations_Following_Initial_Diagno"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with arylsulfatase A deficiency (metachromatic leukodystrophy, MLD), the following evaluations are recommended:</p><ul><li class="half_rhythm"><div>If the diagnosis is made presymptomatically, baseline measures of ARSA enzyme activity, urinary sulfatide excretion, and myelin integrity by MRI to monitor disease progression and evaluate the need for possible intervention</div></li><li class="half_rhythm"><div>For those identified presymptomatically or predicted to have late-onset MLD, referral for HSCT evaluation, preferably at an institution with expertise in allogenic HSCT in individuals with metabolic disorders</div></li><li class="half_rhythm"><div>Baseline assessment of development/cognitive abilities and behavior to monitor disease progression or changes with attempted therapy</div></li><li class="half_rhythm"><div>Peripheral nervous system evaluation</div></li><li class="half_rhythm"><div>Hearing assessment</div></li><li class="half_rhythm"><div>Visual assessment</div></li><li class="half_rhythm"><div>Consultation with a clinical or biochemical geneticist and/or genetic counselor</div></li></ul><p><b>Guidelines.</b> See <a class="bk_pop" href="#mld.REF.wang.2011">Wang et al [2011]</a> for clinical follow-up recommendations. Click <a href="http://www.nature.com/gim/journal/v13/n5/pdf/gim9201178a.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">here</a> for full text.</p></div><div id="mld.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>Whether the intent is to prolong life or to let the disease run its natural course, an extended period of nursing care with changing needs can be anticipated. Supportive therapies to maximize the retention of physical and neuromuscular functions help avoid many end-stage care problems.</p><p>Every effort should be made to maintain intellectual abilities, neuromuscular function, and mobility as long as possible. Provision of an enriched environment and an aggressive physical therapy program provides an optimized quality of life at all stages of the disease. The parents and/or caregivers should be aware of the likely progression of the disorder to anticipate decisions concerning walking aids, car seats, wheelchairs, suction equipment, swallowing aids, feeding tubes, and other supportive measures.</p><p>Seizures and contractures should be treated with antiepileptic drugs and muscle relaxants, respectively. Gastroesophageal reflux, constipation, and drooling are common problems that may be helped by specific medical or surgical interventions.</p><p>The <a href="http://www.evanoskyfoundation.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Evanosky Foundation</a> has a very helpful document, <a href="http://www.evanoskyfoundation.org/content/3-mld/2-care/mld-care-plan-031408.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Suggestions for Caring for a Child with MLD</a> (pdf), based on their family&#x02019;s experience.</p><p>Because MLD affects the whole family, management should include a team of professionals to provide <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> and family support through what is often a long disease process. Even children with late-infantile MLD may survive for five to ten years with progressive loss of function and continually changing care needs.</p><p>Affected individuals remain susceptible to the full range of childhood and adult diseases. A pediatrician or family physician should be involved in developing comprehensive care plans &#x02013;including the usual regime of age-appropriate vaccinations, flu shots, nutritional support, and other typical medical care. Dental care is important and is often difficult to obtain. Pulmonary function and vision may also need attention.</p><p>It is important for most families to develop a network of support services and establish contact with other families who have faced similar situations.</p></div><div id="mld.Prevention_of_Primary_Manifestations"><h3>Prevention of Primary Manifestations</h3><p><b>Hematopoietic stem cell transplantation (HSCT)</b> is an available therapy that attempts to treat the primary central nervous system (CNS) manifestations of MLD. Despite significant improvement in allogeneic transplantation, this therapy remains controversial because:</p><ul><li class="half_rhythm"><div>Systematic outcome data are limited and difficult to generalize due the use of different eligibility criteria and transplantation protocols;</div></li><li class="half_rhythm"><div>Outcome data from older cohorts do not predict current outcomes given constantly improving transplant-related morbidity and mortality due to advances in donor-recipient HLA typing and matching, conditioning, infectious disease detection and management, and the use of non-<a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> donors; and</div></li><li class="half_rhythm"><div>Different types of MLD have shown different responses.</div></li></ul><p>However, in the absence of alternative approaches, HSCT needs to be discussed with families, particularly with those with slower progressing, late-onset forms of MLD. At-risk relatives can be diagnosed by biochemical or <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> before symptoms occur and could benefit most from this intervention. Despite mounting evidence of utility, HSCT is not expected to fully abrogate the manifestations of the disease.</p><p><b>Late-infantile MLD.</b> Allogenic HSCT even at a presymptomatic stage has been shown to be ineffective and is not recommended [<a class="bk_pop" href="#mld.REF.bredius.2007.309">Bredius et al 2007</a>, <a class="bk_pop" href="#mld.REF.van_rappard.2016a.3098">van Rappard et al 2016a</a>]. Disease progression in late-infantile MLD is faster than the pace of engraftment and subsequent CNS migration of bone marrow-derived monocyte/macrophages, even in clinically asymptomatic individuals.</p><p><b>Juvenile and adult MLD.</b> Taken together the data support that HSCT is a relatively safe procedure for individuals with pre- and early symptomatic MLD with the juvenile or adult form of the disease [<a class="bk_pop" href="#mld.REF.g_rg.2007.1139">G&#x000f6;rg et al 2007</a>, <a class="bk_pop" href="#mld.REF.pierson.2008.583">Pierson et al 2008</a>, <a class="bk_pop" href="#mld.REF.cable.2011.207">Cable et al 2011</a>, <a class="bk_pop" href="#mld.REF.kr_gelohmann.2013.369">Kr&#x000e4;geloh-Mann et al 2013</a>, <a class="bk_pop" href="#mld.REF.martin.2013.616">Martin et al 2013</a>, <a class="bk_pop" href="#mld.REF.solders.2014.1046">Solders et al 2014</a>, <a class="bk_pop" href="#mld.REF.boucher.2015.94">Boucher et al 2015</a>, <a class="bk_pop" href="#mld.REF.chen.2016.338">Chen et al 2016</a>, <a class="bk_pop" href="#mld.REF.groeschel.2016.1133">Groeschel et al 2016</a>, <a class="bk_pop" href="#mld.REF.van_rappard.2016a.3098">van Rappard et al 2016a</a>]. In these clinical types, HSCT can result in disease stabilization and high disease-burden-free survival. Compared with nontransplanted individuals, the transplanted individuals are less likely to lose their gross motor or language function and demonstrate significantly lower MRI severity scores. Motor and cognitive function at the time of HSCT evaluation are good predictors of outcome: <a class="bk_pop" href="#mld.REF.van_rappard.2016a.3098">Van Rappard et al [2016a]</a> propose that patients with <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> motor (inability to walk without support) and cognitive (IQ &#x0003c;75) function receive no benefit from HSCT. Brain stem auditory evoked responses, visual evoked potentials, electroencephalogram, and/or peripheral nerve conduction velocities have been shown to stabilize or improve in individuals with juvenile MLD [<a class="bk_pop" href="#mld.REF.martin.2013.616">Martin et al 2013</a>]. Long-term neuroimaging after HSCT suggest that remyelination occurs [<a class="bk_pop" href="#mld.REF.ding.2012.257">Ding et al 2012</a>].</p><p>Regardless of clinical type, HSCT should not be offered to individuals with significant neurologic involvement at the time of evaluation. Engraftment has been shown to require myeloablative conditioning most commonly utilizing full-dose busulfan, which crosses the blood-brain barrier [<a class="bk_pop" href="#mld.REF.boelens.2016.285">Boelens &#x00026; van Hasselt 2016</a>]. This can result in further neurologic decline.</p></div><div id="mld.Prevention_of_Secondary_Complication"><h3>Prevention of Secondary Complications</h3><p>Therapies designed to prevent decline in mobility, cognitive ability, communication, or food intake are considered to be most beneficial by caregivers and physicians [<a class="bk_pop" href="#mld.REF.eichler.2016.1457">Eichler et al 2016</a>].</p><p>Implement safety measures for gait or movement limitations as well as seizure precautions.</p><p>Affected individuals remain susceptible to the full range of childhood and adult diseases. The pediatrician or general care physician should be involved in developing comprehensive care plans.</p><p>For further information on the specific nursing care requirements for those with MLD who undergo HCST or in late stages of the disease, see <a class="bk_pop" href="#mld.REF.barrell.2007.64">Barrell [2007]</a>.</p><p>Anesthesia (if required) should be administered by an experienced anesthesiologist: exacerbation of symptoms has been noted following anesthesia, as <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals may have altered responses to sedatives and anesthetics [<a class="bk_pop" href="#mld.REF.mattioli.2007.64">Mattioli et al 2007</a>, <a class="bk_pop" href="#mld.REF.birkholz.2009.551">Birkholz et al 2009</a>, <a class="bk_pop" href="#mld.REF.cappuccio.2013.113">Cappuccio et al 2013</a>].</p></div><div id="mld.Surveillance"><h3>Surveillance</h3><p>Individuals with MLD should be followed at regular intervals by a neurologist and a metabolic geneticist.</p><p>Periodic brain MRI examination to monitor the status of CNS demyelination should be performed. The MLD MR severity scoring method can be used to provide a measure of brain involvement in these individuals [<a class="bk_pop" href="#mld.REF.eichler.2009.1893">Eichler et al 2009</a>] to allow for monitoring disease evolution and response to therapy.</p><p>Monitor for changes in motor function that could indicate a need to alter care and support systems (e.g., introduction of walking aids and/or a wheelchair). A classification system for gross motor function for children with MLD (GMFC-MLD) has been developed and tested by <a class="bk_pop" href="#mld.REF.kehrer.2011b.156">Kehrer et al [2011b]</a>; it can be used to monitor the course of the disease and should prove useful in evaluating and comparing therapeutic trials.</p><p>Monitor for onset of seizures and/or contractures, which could indicate a need to change medical management and physical therapy.</p><p>Monitor for difficulties with feeding or swallowing. Monitor nutritional needs and need for gastrostomy tube placement.</p><p>Special attention is indicated following general anesthesia or an infection with a high fever as these may trigger exacerbation of disease progression.</p></div><div id="mld.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>While environmental factors are thought to influence the onset and severity of MLD symptoms, no specific exacerbating agents are known. Initial symptoms are often noted following a febrile illness or other stress, but it is unclear if a high fever actually accelerates progression.</p><p>Excessive alcohol and drug use are often associated with later-onset MLD, but it is unclear if this is caused by the disease or is simply an attempt at self-medication in the face of increasing cognitive difficulties [<a class="bk_pop" href="#mld.REF.alvarezleal.2001.297">Alvarez-Leal et al 2001</a>].</p></div><div id="mld.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to consider evaluation of apparently asymptomatic sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> to identify those who could potentially benefit from hematopoietic stem cell transplantation (HSCT) and other experimental treatment options. Although substantial risk is involved and long-term effects are unclear, the best clinical outcomes are obtained when HSCT occurs before clinical symptoms have appeared; see <a href="#mld.Prevention_of_Primary_Manifestations">Prevention of Primary Manifestations</a>.</p><p>Evaluations can include the following:</p><ul><li class="half_rhythm"><div>Perform <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> if the pathogenic variants in the family are known.</div></li><li class="half_rhythm"><div>If the pathogenic variants in the family are not known, work up should begin with measurement of urinary excretion of sulfatides.</div></li><li class="half_rhythm"><div>Measurement of ARSA in peripheral blood leukocytes or cultured fibroblasts can support the diagnosis but is not sufficient by itself. See <a href="#mld.Suggestive_Findings">Suggestive Findings</a>, <b>ARSA enzyme pseudodeficiency.</b></div></li><li class="half_rhythm"><div>Presymptomatically identified individuals should be followed regularly by a neurologist and a metabolic geneticist.</div></li><li class="half_rhythm"><div>Those predicted to have juvenile and late-onset MLD based on family history or <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> should be referred for HSCT evaluation.</div></li><li class="half_rhythm"><div>Periodic brain MRI examination to monitor the status of CNS demyelination to allow for scoring and monitoring of response to therapy.</div></li></ul><p>See <a href="#mld.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="mld.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Attempts at improving the effectiveness of HSCT include genetic modification of autologous hematopoietic stem and progenitor cells using <a class="def" href="/books/n/gene/glossary/def-item/gene-therapy/">gene therapy</a>, combination with intrathecal enzyme replacement, or intrathecal cell transplantation.</p><p><b><i>Ex vivo</i> <a class="def" href="/books/n/gene/glossary/def-item/gene-therapy/">gene therapy</a>.</b> Gene therapy is the delivery of genetic material using viral vectors to an individual&#x02019;s cells or tissue for therapeutic purposes; it can be accomplished using <i>ex vivo</i> or <i>in vivo</i> approaches. <i>Ex vivo</i> modification of autologous hematopoietic stem and progenitor cells using a lentivirus expressing functional ARSA enzyme is currently being tested in Phase I/II clinical trials with promising results. An ad hoc analysis of the "TIGET-MLD" trial (<a href="https://clinicaltrials.gov/ct2/show/NCT01560182?term=NCT01560182&#x00026;rank=1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a>) was published [<a class="bk_pop" href="#mld.REF.sessa.2016.476">Sessa et al 2016</a>]. It describes nine children with a diagnosis of early-onset disease (6 had late-infantile disease, 2 had early-juvenile disease, and 1 had early-onset disease that could not be definitively classified). At the time of analysis, all children had survived, with a median follow up of 36 months (range 18-54 months). The studies showed reconstitution of ARSA activity in hematopoietic cells and in the cerebrospinal fluid. Compared to historical untreated controls, eight individuals, seven of whom received treatment when presymptomatic, had prevention of disease onset or halted disease progression. The Gross Motor Function Measurement (GMFM) scores for six individuals was like that of normally developing children. Electroneurographic studies of peripheral nerves documented improvement in three individuals.</p><p><b><i>In vivo</i> <a class="def" href="/books/n/gene/glossary/def-item/gene-therapy/">gene therapy</a>.</b> Allogeneic HSCT and autologous HSCT with gene-corrected cells is showing great benefit, primarily in presymptomatic individuals. These are promising therapies for individuals identified at presymptomatic stages with a family history of MLD or perhaps individuals identified on future <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a>. Unfortunately, most individuals diagnosed with MLD have no family history of MLD. Hence, most children with severe forms of MLD would not be diagnosed at the presymptomatic phase of the disease, making it unlikely for this therapeutic option to be offered or effective for many individuals with MLD. Accordingly, there is a need for therapies that can get to the brain quickly. One way to achieve this is with <i>in vivo</i> gene therapy via intrathecal or intracerebral delivery of viral vectors. TG-MLD (<a href="https://clinicaltrials.gov/ct2/show/NCT01801709?term=NCT01801709&#x00026;rank=1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a>) is testing the delivery of an adeno-associated virus serotype rh.10 (AAVrh.10) vector to transfer the <a class="def" href="/books/n/gene/glossary/def-item/cdna/">cDNA</a> coding for ARSA enzyme in children <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> with early onset forms of MLD.</p><p><b>Enzyme replacement therapy (ERT).</b> An alternative to <i>in vivo</i> <a class="def" href="/books/n/gene/glossary/def-item/gene-therapy/">gene therapy</a> is ERT. For the most part ERT has been considered impractical because of the difficulty of bypassing the blood-brain barrier. Clinical testing of intravenous recombinant human enzyme was discontinued in 2010 after a Phase I/II study failed to show substantial improvement (see <a href="http://www.mldfoundation.org/pdfs/Shire-HGT_HGT-1111%20_statement_2010-02-19.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Shire HGT MLD Update 2010</a>). However, different forms of human ARSA enzyme are now available, and animal studies suggest that it may be a useful supplement for HSCT [<a class="bk_pop" href="#mld.REF.martino.2005.243">Martino et al 2005</a>, <a class="bk_pop" href="#mld.REF.matzner.2005.1139">Matzner et al 2005</a>]. Intrathecal delivery of the enzyme is being tested in individuals with late infantile form (<a href="https://clinicaltrials.gov/ct2/show/NCT01560182?term=NCT01560182&#x00026;rank=1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a>). The efficacy and safety of intravenous ERT is being tested in an individual with late infantile MLD who had received HSCT at a presymptomatic stage of the disease (<a href="https://clinicaltrials.gov/ct2/show/NCT01303146?term=NCT01303146&#x00026;rank=1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a>).</p><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions.</p><p><b>Other: therapies under preclinical investigation</b></p><ul><li class="half_rhythm"><div>Intracerebral delivery of AAV5 vector encoding human ARSA in non-human primates [<a class="bk_pop" href="#mld.REF.colle.2010.147">Colle et al 2010</a>]</div></li><li class="half_rhythm"><div>Enzyme replacement using a single intracerebroventricular injection of self-complementary AAV1 vector in the CSF in a mouse model of MLD [<a class="bk_pop" href="#mld.REF.hironaka.2015.13104">Hironaka et al 2015</a>]</div></li><li class="half_rhythm"><div>Neonatal systemic injection of an AAV serotype 9 vector in an MLD mouse model [<a class="bk_pop" href="#mld.REF.miyake.2014.427">Miyake et al 2014</a>]</div></li></ul></div></div><div id="mld.Genetic_Counseling"><h2 id="_mld_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="mld.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Arylsulfatase A deficiency (MLD) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p></div><div id="mld.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child are usually obligate heterozygotes (i.e., carriers of one <i>ARSA</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The offspring of an individual with arylsulfatase A deficiency are obligate heterozygotes (carriers) for a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>ARSA</i>.</p><p><b>Other family members.</b> Each sib of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of an <i>ARSA</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p></div><div id="mld.Carrier_Heterozygote_Detection"><h3>Carrier (Heterozygote) Detection</h3><p><b>Molecular genetic testing.</b> Carrier testing for at-risk relatives requires prior identification of the <i>ARSA</i> pathogenic variants in the family. In instances of apparent homozygosity for an MLD-causing <i>ARSA</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>, it is appropriate either to establish the presence of the <i>ARSA</i> pathogenic variant in both parents or to confirm the presence of two alleles in the proband by performing <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> to rule out deletion of one <i>ARSA</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>. This is important in clarifying the genetic status of at-risk relatives.</p><p><b>Biochemical testing.</b> Analysis of arylsulfatase A enzyme activity in leukocytes or cultured fibroblasts for <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> detection is fairly reliable if the range of enzyme activity within a family is known; however, it is much less reliable for testing individuals with no family history of MLD because of the substantial variation in "normal" enzyme activity resulting from the high frequency of pseudodeficiency alleles.</p></div><div id="mld.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#mld.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="mld.Prenatal_Testing_and_Preimplantation"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p><b>Molecular genetic testing.</b> Once the <i>ARSA</i> pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for MLD are possible.</p><p><b>Biochemical testing.</b> Analysis of arylsulfatase A enzyme activity in cultured amniotic fluid cells or chorionic villus cells has been used for the <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> of arylsulfatase A deficiency. Cells for culturing are obtained by amniocentesis (usually performed at ~15-18 weeks' gestation) or chorionic villus sampling (usually performed at ~10-12 weeks' gestation). The chief limitation to this approach is the need to grow sufficient cells for testing, which may take two to three weeks after amniocentesis or CVS sampling [<a class="bk_pop" href="#mld.REF.besley.1991.128">Besley et al 1991</a>].</p><p>Note: Gestational age is expressed as menstrual weeks calculated either from the first day of the last normal menstrual period or by ultrasound measurements.</p><p>If one parent has a very low level of arylsulfatase A enzyme activity caused by a pseudodeficiency <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>, <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> using the assay of enzyme activity is unreliable. Either sulfatide loading of the cultured cells or <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> can be used in these instances to clarify diagnostic issues.</p></div></div><div id="mld.Resources"><h2 id="_mld_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Medline Plus</b></div><div><a href="http://www.nlm.nih.gov/medlineplus/ency/article/001205.htm" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Metachromatic leukodystrophy</a></div></li><li class="half_rhythm"><div><b>MLD Foundation</b></div><div>21345 Miles Drive</div><div>West Linn OR 97068-2878</div><div><b>Phone:</b> 800-617-8387 (toll-free); 503-656-4808</div><div><b>Fax:</b> 503-212-0159</div><div><b>Email:</b> info@mldfoundation.org</div><div><a href="http://www.mldfoundation.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.mldfoundation.org</a></div></li><li class="half_rhythm"><div><b>National Institute of Neurological Disorders and Stroke (NINDS)</b></div><div>PO Box 5801</div><div>Bethesda MD 20824</div><div><b>Phone:</b> 800-352-9424 (toll-free); 301-496-5751; 301-468-5981 (TTY)</div><div><a href="https://www.ninds.nih.gov/Disorders/All-Disorders/Metachromatic-Leukodystrophy-Information-Page" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Metachromatic Leukodystrophy Information Page</a></div></li><li class="half_rhythm"><div><b>Canadian MPS Society</b></div><div>#218-2055 Commercial Drive</div><div>Vancouver British Columbia V5N 0C7</div><div>Canada</div><div><b>Phone:</b> 800-667-1846; 604-924-5130</div><div><b>Email:</b> info@mpssociety.ca</div><div><a href="http://www.mpssociety.ca" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.mpssociety.ca</a></div></li><li class="half_rhythm"><div><b>European Leukodystrophy Association (ELA)</b></div><div>2, rue Mi-les-Vignes</div><div>B.P. 61024</div><div>Laxou Cedex 54521</div><div>France</div><div><b>Phone:</b> 03833093 34</div><div><b>Fax:</b> 03833000 68</div><div><b>Email:</b> ela@ela-asso.com</div><div><a href="http://www.ela-asso.com" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ela-asso.com</a></div></li><li class="half_rhythm"><div><b>Hunter's Hope Foundation</b></div><div>6368 West Quaker Street</div><div>PO Box 643</div><div>Orchard Park NY 14127</div><div><b>Phone:</b> 877-984-4673 (toll-free); 716-667-1200</div><div><b>Fax:</b> 716-667-1212</div><div><b>Email:</b> info@huntershope.org</div><div><a href="http://www.huntershope.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.huntershope.org</a></div></li><li class="half_rhythm"><div><b>United Leukodystrophy Foundation (ULF)</b></div><div>224 North Second Street</div><div>Suite 2</div><div>DeKalb IL 60115</div><div><b>Phone:</b> 800-728-5483 (toll-free); 815-748-3211</div><div><b>Fax:</b> 815-748-0844</div><div><b>Email:</b> office@ulf.org</div><div><a href="http://www.ulf.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ulf.org</a></div></li><li class="half_rhythm"><div><b>Myelin Disorders Bioregistry Project</b></div><div><b>Email:</b> myelindisorders@cnmc.org</div><div><a href="https://www.chop.edu/research/myelin-disorders-biorepository-project" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Myelin Disorders Bioregistry Project</a></div></li></ul></div><div id="mld.Molecular_Genetics"><h2 id="_mld_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="mld.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Arylsulfatase A Deficiency: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1130/table/mld.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__mld.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_mld.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_mld.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_mld.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_mld.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_mld.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_mld.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_mld.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/410" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>ARSA</i></a></td><td headers="hd_b_mld.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=410" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">22q13<wbr style="display:inline-block"></wbr>​.33</a></td><td headers="hd_b_mld.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P15289" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Arylsulfatase A</a></td><td headers="hd_b_mld.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/ARSA" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ARSA database</a></td><td headers="hd_b_mld.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=ARSA" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ARSA</a></td><td headers="hd_b_mld.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=ARSA[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ARSA</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="mld.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="mld.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Arylsulfatase A Deficiency (<a href="/omim/250100,607574" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1130/table/mld.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__mld.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/250100" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">250100</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">METACHROMATIC LEUKODYSTROPHY; MLD</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/607574" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">607574</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">ARYLSULFATASE A; ARSA</td></tr></tbody></table></div></div><div id="mld.Molecular_Pathogenesis"><h3>Molecular Pathogenesis</h3><p>The molecular pathogenic processes involved in MLD are poorly understood. While the accumulation of sulfatides in oligodendrocytes and Schwann cells is thought to somehow be responsible for the loss of these cells and the resultant demyelination, these lipids have not proven to be toxic in cell cultures. Psychosine sulfate (lyso-sulfatide) is elevated in tissues from individuals with MLD, and a cytotoxic role parallel to that of psychosine in <a href="/books/n/gene/krabbe/">Krabbe disease</a> has been suggested. Neuroinflammation has also been proposed based on experiments in murine models of MLD [<a class="bk_pop" href="#mld.REF.stein.2015.1160">Stein et al 2015</a>].</p><p><b>Gene structure.</b>
<i>ARSA</i> contains eight exons in a relatively short <a class="def" href="/books/n/gene/glossary/def-item/coding-region/">coding region</a> of 3.2 kilobases (kb) and is translated to a 2.1-kb <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a>. The 5' untranslated region is typical of a housekeeping <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> but lacks a TATA or CAAT box typical of lysosomal enzymes. The gene extends for nearly 3 kb beyond the stop codon. Additional mRNA products of 3.7 and 4.8 kb are detected in cells; their significance has not been investigated. For a detailed summary of gene and protein information, see <a href="/books/NBK1130/#mld.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Benign and pseudodeficiency variants.</b> Several variants of <i>ARSA</i> have been identified (see <a class="figpopup" href="/books/NBK1130/table/mld.T.selected_arsa_variants/?report=objectonly" target="object" rid-figpopup="figmldTselectedarsavariants" rid-ob="figobmldTselectedarsavariants">Table 3</a>). Other synonymous variants have also been reported (see <a href="/books/NBK1130/#mld.molgen.TA">Table A</a>, <b>ClinVar</b>).</p><p><b>Pathogenic variants.</b> At least 200 <i>ARSA</i> pathogenic variants associated with arylsulfatase A deficiency have been reported [<a class="bk_pop" href="#mld.REF.cesani.2016.16">Cesani et al 2016</a>]. Disease-causing <i>ARSA</i>-MLD variants are as likely to be found in <a class="def" href="/books/n/gene/glossary/def-item/cis/"><i>cis</i></a> configuration with an <i>ARSA</i>-PD sequence variant as in wild type alleles. Complete <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of one copy of <i>ARSA</i> has been reported in a few individuals with MLD [<a class="bk_pop" href="#mld.REF.coultermackie.1995.787">Coulter-Mackie et al 1995</a>, <a class="bk_pop" href="#mld.REF.eng.2004.95">Eng et al 2004</a>, <a class="bk_pop" href="#mld.REF.bisgaard.2009.175">Bisgaard et al 2009</a>]. One case of intragenic <a class="def" href="/books/n/gene/glossary/def-item/recombination/">recombination</a> leading to <a class="def" href="/books/n/gene/glossary/def-item/somatic-mosaicism/">somatic mosaicism</a> has been reported [<a class="bk_pop" href="#mld.REF.regis.2006.150">Regis et al 2006</a>].</p><div id="mld.T.selected_arsa_variants" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Selected <i>ARSA</i> Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1130/table/mld.T.selected_arsa_variants/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__mld.T.selected_arsa_variants_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_mld.T.selected_arsa_variants_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Variant<br />Classification</th><th id="hd_h_mld.T.selected_arsa_variants_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change<br />(Alias&#x000a0;<sup>1</sup>)</th><th id="hd_h_mld.T.selected_arsa_variants_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_mld.T.selected_arsa_variants_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_mld.T.selected_arsa_variants_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Benign and pseudodeficiency</b><br /><b>(<i>ARSA</i>-PD)</b></td><td headers="hd_h_mld.T.selected_arsa_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1049A&#x0003e;G&#x000a0;<sup>2,&#x000a0;3</sup></td><td headers="hd_h_mld.T.selected_arsa_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Asn350Ser</td><td headers="hd_h_mld.T.selected_arsa_variants_1_1_1_4" rowspan="15" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_000487.4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000487<wbr style="display:inline-block"></wbr>​.4</a><br /><a href="/protein/NP_000478.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000478<wbr style="display:inline-block"></wbr>​.2</a></td></tr><tr><td headers="hd_h_mld.T.selected_arsa_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.1172C&#x0003e;G&#x000a0;<sup>4</sup></td><td headers="hd_h_mld.T.selected_arsa_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Thr391Ser</td></tr><tr><td headers="hd_h_mld.T.selected_arsa_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.*96A&#x0003e;G&#x000a0;<sup>3</sup><br />(c.1524+96A&#x0003e;G)</td><td headers="hd_h_mld.T.selected_arsa_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td></tr><tr><td headers="hd_h_mld.T.selected_arsa_variants_1_1_1_1" rowspan="12" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Pathogenic</b><br /><b>(<i>ARSA</i>-MLD)</b></td><td headers="hd_h_mld.T.selected_arsa_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.251G&#x0003e;A</td><td headers="hd_h_mld.T.selected_arsa_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg84Gln</td></tr><tr><td headers="hd_h_mld.T.selected_arsa_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.287C&#x0003e;T</td><td headers="hd_h_mld.T.selected_arsa_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ser96Phe</td></tr><tr><td headers="hd_h_mld.T.selected_arsa_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.296G&#x0003e;A</td><td headers="hd_h_mld.T.selected_arsa_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly99Asp</td></tr><tr><td headers="hd_h_mld.T.selected_arsa_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.459+1G&#x0003e;A</td><td headers="hd_h_mld.T.selected_arsa_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td></tr><tr><td headers="hd_h_mld.T.selected_arsa_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.536T&#x0003e;G</td><td headers="hd_h_mld.T.selected_arsa_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ile179Ser</td></tr><tr><td headers="hd_h_mld.T.selected_arsa_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.635C&#x0003e;T</td><td headers="hd_h_mld.T.selected_arsa_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ala212Val</td></tr><tr><td headers="hd_h_mld.T.selected_arsa_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.733G&#x0003e;A</td><td headers="hd_h_mld.T.selected_arsa_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly245Arg</td></tr><tr><td headers="hd_h_mld.T.selected_arsa_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.763G&#x0003e;C</td><td headers="hd_h_mld.T.selected_arsa_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Asp255His</td></tr><tr><td headers="hd_h_mld.T.selected_arsa_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.1204+1G&#x0003e;A</td><td headers="hd_h_mld.T.selected_arsa_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td></tr><tr><td headers="hd_h_mld.T.selected_arsa_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.1226C&#x0003e;T</td><td headers="hd_h_mld.T.selected_arsa_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Thr409Ile</td></tr><tr><td headers="hd_h_mld.T.selected_arsa_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.1277C&#x0003e;T</td><td headers="hd_h_mld.T.selected_arsa_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Pro426Leu</td></tr><tr><td headers="hd_h_mld.T.selected_arsa_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.1401_1411del<br />(1401del11bp)</td><td headers="hd_h_mld.T.selected_arsa_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ala468LeufsTer84</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the author. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="mld.TF.3.1"><p class="no_margin">Variant designation that does not conform to current naming conventions</p></div></dd><dt>2. </dt><dd><div id="mld.TF.3.2"><p class="no_margin">c.1049A&#x0003e;G (<i>ARSA</i>-PD glycosylation site alteration) is a common <a class="def" href="/books/n/gene/glossary/def-item/benign-variant/">benign variant</a> occurring in 15%-40% of individuals, depending on the population studied.</p></div></dd><dt>3. </dt><dd><div id="mld.TF.3.3"><p class="no_margin">The most common <i>ARSA-</i>PD <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> in the European and American populations has two sequence variants in <a class="def" href="/books/n/gene/glossary/def-item/cis/"><i>cis</i></a> configuration (i.e., on the same <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a>), designated as c.[1049A&#x0003e;G; *96A&#x0003e;G].</p></div></dd><dt>4. </dt><dd><div id="mld.TF.3.4"><p class="no_margin">Found in approximately half of the Euro/American population initially studied</p></div></dd></dl></div></div></div><div id="mld.T.distribution_of_the_most_common_ar" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p>Distribution of the Most Common <i>ARSA</i> Pathogenic Variants in Various Populations</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1130/table/mld.T.distribution_of_the_most_common_ar/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__mld.T.distribution_of_the_most_common_ar_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_1" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Pathogenic Variant</th><th id="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">% Late-Infantile</th><th id="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">% Juvenile</th><th id="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">% Adult</th><th id="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">% All MLD Alleles</th><th id="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_6" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference &#x02013; Ethnicity&#x000a0;<sup>1</sup> (# of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals)</th></tr></thead><tbody><tr><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_1" rowspan="18" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>European</b></td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_1" rowspan="6" colspan="1" style="text-align:left;vertical-align:middle;">c.459+1G&#x0003e;A</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">15</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#mld.REF.draghia.1997.234">Draghia et al [1997]</a> (21)</td></tr><tr><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">39</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">11</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">19</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#mld.REF._ugowska.2005b.48">&#x00141;ugowska et al [2005b]</a> &#x02013; P (43)</td></tr><tr><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">40</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">16</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">9</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">25</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#mld.REF._ugowska.2005a.353">&#x00141;ugowska et al [2005a]</a> &#x02013; Eu (384)</td></tr><tr><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">29</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">8</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">16</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#mld.REF.berger.1997.335">Berger et al [1997]</a> (25)</td></tr><tr><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">45</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">16</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">28</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#mld.REF.polten.1991.18">Polten et al [1991]</a> (66)</td></tr><tr><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">19.7</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">[<a class="bk_pop" href="#mld.REF.cesani.2009.e936">Cesani et al 2009</a>] (432)</td></tr><tr><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_1" rowspan="6" colspan="1" scope="row" style="text-align:left;vertical-align:middle;">p.Pro426Leu</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">15</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#mld.REF.draghia.1997.234">Draghia et al [1997]</a></td></tr><tr><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">0</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">14</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">45</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">17</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#mld.REF._ugowska.2005b.48">&#x00141;ugowska et al [2005b]</a> &#x02013; P</td></tr><tr><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">0</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">30</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">42.5</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">18.6</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#mld.REF._ugowska.2005a.353">&#x00141;ugowska et al [2005a]</a> &#x02013; Eu</td></tr><tr><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">7</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">15</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">60</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">26</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#mld.REF.berger.1997.335">Berger et al [1997]</a> (25)</td></tr><tr><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">0</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">34</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">59</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">27</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#mld.REF.polten.1991.18">Polten et al [1991]</a> (66)</td></tr><tr><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">12.2</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">[<a class="bk_pop" href="#mld.REF.cesani.2009.e936">Cesani et al 2009</a>] (432)</td></tr><tr><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_1" rowspan="2" colspan="1" scope="row" style="text-align:left;vertical-align:middle;">c.1204+1G&#x0003e;A</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">11</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#mld.REF._ugowska.2005b.48">&#x00141;ugowska et al [2005b]</a> &#x02013; P</td></tr><tr><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#mld.REF.fluharty.1991.1340">Fluharty et al [1991]</a> (~100)</td></tr><tr><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_1" rowspan="4" colspan="1" scope="row" style="text-align:left;vertical-align:middle;">p.Ile179Ser</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">17</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">23</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">13</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#mld.REF._ugowska.2005b.48">&#x00141;ugowska et al [2005b]</a> &#x02013; P</td></tr><tr><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">0</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">15</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">30</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">12</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#mld.REF.berger.1997.335">Berger et al [1997]</a> (25)</td></tr><tr><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#mld.REF.fluharty.1991.1340">Fluharty et al [1991]</a> (~100)</td></tr><tr><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">[<a class="bk_pop" href="#mld.REF.cesani.2009.e936">Cesani et al 2009</a>] (432)</td></tr><tr><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_1" rowspan="6" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Japanese</b></td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_1" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly99Asp</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">40</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#mld.REF.eto.1993.179">Eto et al [1993]</a> (10)</td></tr><tr><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">45.5</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#mld.REF.kurosawa.1998.781">Kurosawa et al [1998]</a> (11)</td></tr><tr><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.459+1G&#x0003e;A</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">10</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#mld.REF.eto.1993.179">Eto et al [1993]</a> (10)</td></tr><tr><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_1" rowspan="2" colspan="1" scope="row" style="text-align:left;vertical-align:middle;">p.Gly245Arg</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#mld.REF.eto.1993.179">Eto et al [1993]</a> (10)</td></tr><tr><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">9</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#mld.REF.kurosawa.1998.781">Kurosawa et al [1998]</a> (11)</td></tr><tr><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">p.Thr409Ile</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">9</td><td headers="hd_h_mld.T.distribution_of_the_most_common_ar_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#mld.REF.kurosawa.1998.781">Kurosawa et al [1998]</a> (11)</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="mld.TF.4.1"><p class="no_margin">P = Polish population; Eu = western European population</p></div></dd></dl></div></div></div><p>For additional information on pathogenic variants commonly found in specific populations, see:</p><ul><li class="half_rhythm"><div><a class="bk_pop" href="#mld.REF.artigal_s.2010.s257">Artigal&#x000e1;s et al [2010]</a> (Brazil)</div></li><li class="half_rhythm"><div><a class="bk_pop" href="#mld.REF.barth.1993.73">Barth et al [1993]</a> (Britain)</div></li><li class="half_rhythm"><div><a class="bk_pop" href="#mld.REF.shukla.2011.38">Shukla et al [2011]</a> (India)</div></li><li class="half_rhythm"><div><a class="bk_pop" href="#mld.REF.bertelli.2006.443">Bertelli et al [2006]</a>, <a class="bk_pop" href="#mld.REF.biffi.2008.349">Biffi et al [2008]</a>, <a class="bk_pop" href="#mld.REF.grossi.2008.e220">Grossi et al [2008]</a> (Italy)</div></li><li class="half_rhythm"><div><a class="bk_pop" href="#mld.REF.marc_o.1999.337">Marc&#x000e3;o et al [1999]</a> (Portugal)</div></li><li class="half_rhythm"><div><a class="bk_pop" href="#mld.REF.gort.1999.240">Gort et al [1999]</a> (Spain)</div></li><li class="half_rhythm"><div><a class="bk_pop" href="#mld.REF.olkhovich.2003.360">Olkhovich et al [2003]</a> (Ukraine)</div></li><li class="half_rhythm"><div><a class="bk_pop" href="#mld.REF.coultermackie.2003.91">Coulter-Mackie &#x00026; Gagnier [2003]</a> (Canada)</div></li><li class="half_rhythm"><div><a class="bk_pop" href="#mld.REF.wang.2007.397">Wang et al [2007]</a> (China)</div></li><li class="half_rhythm"><div><a class="bk_pop" href="#mld.REF.tsuda.1996.400">Tsuda et al [1996]</a>, <a class="bk_pop" href="#mld.REF.kurosawa.1998.781">Kurosawa et al [1998]</a>, <a class="bk_pop" href="#mld.REF.niida.2012.687">Niida et al [2012]</a> (Taiwan)</div></li><li class="half_rhythm"><div><a class="bk_pop" href="#mld.REF.zlotogora.1995.137">Zlotogora et al [1995]</a> (Israel)</div></li><li class="half_rhythm"><div><a class="bk_pop" href="#mld.REF.lugowska.2010.394">Lugowska et al [2010]</a> (Poland)</div></li></ul><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Arylsulfatase A has a precursor polypeptide of approximately 62 kd that is processed by N-linked glycosylation, phosphorylation, sulfation, and proteolytic cleavage to a complex mixture of <a class="def" href="/books/n/gene/glossary/def-item/isoforms/">isoforms</a> that differs from tissue to tissue. A magnesium or calcium ion also becomes tightly bound near the active site. During postsynthetic processing, the Cys69 must be converted to formylglycine before the sulfatase becomes active [<a class="bk_pop" href="#mld.REF.lukatela.1998.3654">Lukatela et al 1998</a>, <a class="bk_pop" href="#mld.REF.dierks.2005.541">Dierks et al 2005</a>].</p><p>As isolated at neutral pH, the arylsulfatase A enzyme is dimeric (~100-120 kd) with two subunits, which may not be identical. At acid pH such as that occurring in the lysosome, the enzyme aggregates further to an octamer, the form present in the crystalline enzyme [<a class="bk_pop" href="#mld.REF.vagedes.2002.3066">Vagedes et al 2002</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> In general, alleles with pathogenic <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants, insertions, or deletions do not produce any active enzyme (I-type <i>ARSA</i>-MLD variants). Approximately half of the variants involving an amino acid substitution also fall into this class but are more likely to express an immuno-cross-reactive material.</p><p>Between 20% and 25% of the single amino acid changes are associated with a low level (&#x02264;1%) of ARSA enzyme activity (A-type <i>ARSA</i>-MLD variants). In those cases in which the properties of the mutated ARSA enzyme have been explored, processing and stability have been affected, leading to altered enzyme or altered ability of the protein to self-associate and an enhanced turnover of the mutated protein [<a class="bk_pop" href="#mld.REF.von_b_low.2002.9455">von B&#x000fc;low et al 2002</a>, <a class="bk_pop" href="#mld.REF.poeppel.2005.1179">Poeppel et al 2005</a>].</p></div></div><div id="mld.References"><h2 id="_mld_References_">References</h2><div id="mld.Published_Guidelines__Consensus_Stat"><h3>Published Guidelines / Consensus Statements</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="mld.REF.wang.2011">Wang RY, Bodamer OA, Watson MS, Wilcox WR, ACMG Work Group on Diagnostic Confirmation of Lysosomal Storage Diseases. Lysosomal storage diseases: diagnostic confirmation and management of presymptomatic individuals. ACMG Standards and Guidelines. Available <a href="http://www.nature.com/gim/journal/v13/n5/pdf/gim9201178a.pdf" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2011. Accessed 7-3-19. [<a href="/pubmed/21502868" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21502868</span></a>]</div></li></ul></div><div id="mld.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="mld.REF.alvarezleal.2001.297">Alvarez-Leal M, Contreras-Hernandez D, Chavez A, Diaz-Contreras JA, Careaga-Olivares J, Zuniga-Charles MA, Reynoso MC, Hernandez-Tellez A. Leukocyte arylsulfatase A activity in patients with alcohol-related cirrhosis. <span><span class="ref-journal">Am J Hum Biol. </span>2001;<span class="ref-vol">13</span>:297–300.</span> [<a href="/pubmed/11460894" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11460894</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.arbour.2000.173">Arbour LT, Silver K, Hechtman P, Treacy EP, Coulter-Mackie MB. Variable onset of metachromatic leukodystrophy in a Vietnamese family. <span><span class="ref-journal">Pediatr Neurol. </span>2000;<span class="ref-vol">23</span>:173–6.</span> [<a href="/pubmed/11020646" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11020646</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.artigal_s.2010.s257">Artigal&#x000e1;s O, Lagranha VL, Saraiva-Pereira ML, Burin MG, Louren&#x000e7;o CM, van der Linden H Jr, Santos ML, Rosemberg S, Steiner CE, Kok F, de Souza CF, Jardim LB, Giugliani R, Schwartz IV. Clinical and biochemical study of 29 Brazilian patients with metachromatic leukodystrophy. <span><span class="ref-journal">J Inherit Metab Dis. </span>2010;<span class="ref-vol">33</span> Suppl 3:S257–62.</span> [<a href="/pubmed/20596894" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20596894</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.barrell.2007.64">Barrell C. Juvenile metachromatic leukodystrophy: understanding the disease and implications for nursing care. <span><span class="ref-journal">J Pediatr Oncol Nurs. </span>2007;<span class="ref-vol">24</span>:64–9.</span> [<a href="/pubmed/17332420" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17332420</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.barth.1993.73">Barth ML, Fensom A, Harris A. Prevalence of common mutations in the arylsulphatase A gene in metachromatic leukodystrophy patients diagnosed in Britain. <span><span class="ref-journal">Hum Genet. </span>1993;<span class="ref-vol">91</span>:73–7.</span> [<a href="/pubmed/8095918" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8095918</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.berger.1997.335">Berger J, Loschl B, Bernheimer H, Lugowska A, Tylki-Szymanska A, Gieselmann V, Molzer B. Occurrence, distribution, and phenotype of arylsulfatase A mutations in patients with metachromatic leukodystrophy. <span><span class="ref-journal">Am J Med Genet. </span>1997;<span class="ref-vol">69</span>:335–40.</span> [<a href="/pubmed/9096767" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9096767</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.bertelli.2006.443">Bertelli M, Gallo S, Buda A, Cecchin S, Fabbri A, Lapucci C, Andrighetto G, Sidoti V, Lorusso L, Pandolfo M. Novel mutations in the arylsulfatase A gene in eight Italian families with metachromatic leukodystrophy. <span><span class="ref-journal">J Clin Neurosci. </span>2006;<span class="ref-vol">13</span>:443–8.</span> [<a href="/pubmed/16678723" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16678723</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.besley.1991.128">Besley G. T., Young E. P., Fensom A. H., Cooper A. First trimester diagnosis of inherited metabolic disease: Experience in the uk. <span><span class="ref-journal">J Inherit Metab Dis. </span>1991;<span class="ref-vol">14</span>:128–33.</span> [<a href="/pubmed/1886402" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1886402</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.biffi.2008.349">Biffi A, Cesani M, Fumagalli F, Del Carro U, Baldoli C, Canale S, Gerevini S, Amadio S, Falautano M, Rovelli A, Comi G, Roncarolo MG, Sessa M. Metachromatic leukodystrophy - mutation analysis provides further evidence of genotype-phenotype correlation. <span><span class="ref-journal">Clin Genet. </span>2008;<span class="ref-vol">74</span>:349–57.</span> [<a href="/pubmed/18786133" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18786133</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.birkholz.2009.551">Birkholz T, Irouschek A, Knorr C, Schmidt J. Alternative anesthetic management of a child with spastic quadriplegia due to metachromatic leukodystrophy using total intravenous anesthesia. <span><span class="ref-journal">Paediatr Anaesth. </span>2009;<span class="ref-vol">19</span>:551–2.</span> [<a href="/pubmed/19453595" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19453595</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.bisgaard.2009.175">Bisgaard AM, Kirchhoff M, Nielsen JE, Kibaek M, Lund A, Schwartz M, Christensen E. Chromosomal deletion unmasking a recessive disease: 22q13 deletion syndrome and metachromatic leukodystrophy. <span><span class="ref-journal">Clin Genet. </span>2009;<span class="ref-vol">75</span>:175–9.</span> [<a href="/pubmed/19054018" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19054018</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.boelens.2016.285">Boelens JJ, van Hasselt PM. Neurodevelopmental outcome after hematopoietic cell transplantation in inborn errors of metabolism: Current considerations and future perspectives. <span><span class="ref-journal">Neuropediatrics. </span>2016;<span class="ref-vol">47</span>:285–92.</span> [<a href="/pubmed/27308871" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27308871</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.boucher.2015.94">Boucher AA, Miller W, Shanley R, Ziegler R, Lund T, Raymond G, Orchard PJ. Long-term outcomes after allogeneic hematopoietic stem cell transplantation for metachromatic leukodystrophy: The largest single-institution cohort report. <span><span class="ref-journal">Orphanet J Rare Dis. </span>2015;<span class="ref-vol">10</span>:94.</span> [<a href="/pmc/articles/PMC4545855/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4545855</span></a>] [<a href="/pubmed/26245762" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26245762</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.bredius.2007.309">Bredius RG, Laan LA, Lankester AC, Poorthuis BJ, van Tol MJ, Egeler RM, Arts WF. Early marrow transplantation in a pre-symptomatic neonate with late infantile metachromatic leukodystrophy does not halt disease progression. <span><span class="ref-journal">Bone Marrow Transplant. </span>2007;<span class="ref-vol">39</span>:309–10.</span> [<a href="/pubmed/17237829" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17237829</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.cable.2011.207">Cable C, Finkel RS, Lehky TJ, Biassou NM, Wiggs EA, Bunin N, Pierson TM. Unrelated umbilical cord blood transplant for juvenile metachromatic leukodystrophy: a 5-year follow-up in three affected siblings. <span><span class="ref-journal">Mol Genet Metab. </span>2011;<span class="ref-vol">102</span>:207–9.</span> [<a href="/pmc/articles/PMC3053057/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3053057</span></a>] [<a href="/pubmed/21035368" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21035368</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.cappuccio.2013.113">Cappuccio G, Brunetti-Pierri N, Terrone G, Romano A, Andria G, Del Giudice E. Low-dose amitriptyline-induced acute dystonia in a patient with metachromatic leukodystrophy. <span><span class="ref-journal">JIMD Rep. </span>2013;<span class="ref-vol">9</span>:113–6.</span> [<a href="/pmc/articles/PMC3565674/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3565674</span></a>] [<a href="/pubmed/23430556" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23430556</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.cesani.2009.e936">Cesani M, Capotondo A, Plati T, Sergi LS, Fumagalli F, Roncarolo MG, Biffi A. Characterization of new arylsulfatase a gene mutations reinforces genotype-phenotype correlation in metachromatic leukodystrophy. <span><span class="ref-journal">Hum Mutat. </span>2009;<span class="ref-vol">30</span>:E936–45.</span> [<a href="/pubmed/19606494" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19606494</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.cesani.2016.16">Cesani M, Lorioli L, Grossi S, Amico G, Fumagalli F, Spiga I, Biffi A. Mutation update of arsa and psap genes causing metachromatic leukodystrophy. <span><span class="ref-journal">Hum Mutat. </span>2016;<span class="ref-vol">37</span>:16–27.</span> [<a href="/pubmed/26462614" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26462614</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.chen.2016.338">Chen X, Gill D, Shaw P, Ouvrier R, Troedson C. Outcome of early juvenile onset metachromatic leukodystrophy after unrelated cord blood transplantation: A case series and review of the literature. <span><span class="ref-journal">J Child Neurol. </span>2016;<span class="ref-vol">31</span>:338–44.</span> [<a href="/pubmed/26187619" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26187619</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.colle.2010.147">Colle MA, Piguet F, Bertrand L, Raoul S, Bieche I, Dubreil L, Sloothaak D, Bouquet C, Moullier P, Aubourg P, Cherel Y, Cartier N, Sevin C. Efficient intracerebral delivery of AAV5 vector encoding human ARSA in non-human primate. <span><span class="ref-journal">Hum Mol Genet. </span>2010;<span class="ref-vol">19</span>:147–58.</span> [<a href="/pubmed/19837699" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19837699</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.coultermackie.2003.91">Coulter-Mackie MB, Gagnier L. Spectrum of mutations in the arylsulfatase A gene in a Canadian DNA collection including two novel frameshift mutations, a new missence mutation (C488R) and an MLD mutation (R84) in <em>cis</em> with a pseudodeficiency allele. <span><span class="ref-journal">Mol Genet Metab. </span>2003;<span class="ref-vol">79</span>:91–8.</span> [<a href="/pubmed/12809638" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12809638</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.coultermackie.2001.e15">Coulter-Mackie MB, Rip J, Beis MJ, Ferreira P, Ludman MD. Multiple metachromatic leucodystrophy alleles in an unaffected subject: a case of dispermic chimaerism. <span><span class="ref-journal">J Med Genet. </span>2001;<span class="ref-vol">38</span>:E15.</span> [<a href="/pmc/articles/PMC1734879/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1734879</span></a>] [<a href="/pubmed/11333871" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11333871</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.coultermackie.1995.787">Coulter-Mackie MB, Rip J, Ludman MD, Beis J, Cole DE. Metachromatic leucodystrophy (MLD) in a patient with a constitutional ring chromosome 22. <span><span class="ref-journal">J Med Genet. </span>1995;<span class="ref-vol">32</span>:787–91.</span> [<a href="/pmc/articles/PMC1051701/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1051701</span></a>] [<a href="/pubmed/8558556" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8558556</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.dierks.2005.541">Dierks T, Dickmanns A, Preusser-Kunze A, Schmidt B, Mariappan M, von Figura K, Ficner R, Rudolph MG. Molecular basis for multiple sulfatase deficiency and mechanism for formylglycine generation of the human formylglycine-generating enzyme. <span><span class="ref-journal">Cell. </span>2005;<span class="ref-vol">121</span>:541–52.</span> [<a href="/pubmed/15907468" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15907468</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.ding.2012.257">Ding XQ, Bley A, Kohlschutter A, Fiehler J, Lanfermann H. Long-term neuroimaging follow-up on an asymptomatic juvenile metachromatic leukodystrophy patient after hematopoietic stem cell transplantation: Evidence of myelin recovery and ongoing brain maturation. <span><span class="ref-journal">Am J Med Genet A. </span>2012;<span class="ref-vol">158A</span>:257–60.</span> [<a href="/pubmed/22140054" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22140054</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.draghia.1997.234">Draghia R, Letourneur F, Drugan C, Manicom J, Blanchot C, Kahn A, Poenaru L, Caillaud C. Metachromatic leukodystrophy: identification of the first deletion in exon 1 and of nine novel point mutations in the arylsulfatase A gene. <span><span class="ref-journal">Hum Mutat. </span>1997;<span class="ref-vol">9</span>:234–42.</span> [<a href="/pubmed/9090526" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9090526</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.eichler.2009.1893">Eichler F, Grodd W, Grant E, Sessa M, Biffi A, Bley A, Kohlschuetter A, Loes DJ, Kraegeloh-Mann I. Metachromatic leukodystrophy: a scoring system for brain MR imaging observations. <span><span class="ref-journal">AJNR Am J Neuroradiol. </span>2009;<span class="ref-vol">30</span>:1893–7.</span> [<a href="/pubmed/19797797" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19797797</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.eichler.2016.1457">Eichler FS, Cox TM, Crombez E, Dali CI, Kohlschutter A. Metachromatic leukodystrophy: An assessment of disease burden. <span><span class="ref-journal">J Child Neurol. </span>2016;<span class="ref-vol">31</span>:1457–63.</span> [<a href="/pubmed/27389394" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27389394</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.eng.2004.95">Eng B, Heshka T, Tarnopolsky MA, Nakamura LM, Nowaczyk MJ, Waye JS. Infantile metachromatic leukodystrophy (MLD) in a compound heterozygote for the c.459 + 1G &#x0003e; A mutation and a complete deletion of the ARSA gene. <span><span class="ref-journal">Am J Med Genet A. </span>2004;<span class="ref-vol">128A</span>:95–7.</span> [<a href="/pubmed/15211666" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15211666</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.eto.1993.179">Eto Y, Kawame H, Hasegawa Y, Ohashi T, Ida H, Tokoro T. Molecular characteristics in Japanese patients with lipidosis: novel mutations in metachromatic leukodystrophy and Gaucher disease. <span><span class="ref-journal">Mol Cell Biochem. </span>1993;<span class="ref-vol">119</span>:179–84.</span> [<a href="/pubmed/8455580" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8455580</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.fluharty.1991.1340">Fluharty AL, Fluharty CB, Bohne W, von Figura K, Gieselmann V. Two new arylsulfatase A (ARSA) mutations in a juvenile metachromatic leukodystrophy (MLD) patient. <span><span class="ref-journal">Am J Hum Genet. </span>1991;<span class="ref-vol">49</span>:1340–50.</span> [<a href="/pmc/articles/PMC1686463/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1686463</span></a>] [<a href="/pubmed/1684088" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1684088</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.garavelli.2009.284">Garavelli L, Rosato S, Mele A, Wischmeijer A, Rivieri F, Gelmini C, Sandon&#x000e0; F, Sassatelli R, Carlinfante G, Giovanardi F, Gemmi M, Della Giustina E, Amarri S, Banchini G, Bedogni G. Massive hemobilia and papillomatosis of the gallbladder in metachromatic leukodystrophy: a life-threatening condition. <span><span class="ref-journal">Neuropediatrics. </span>2009;<span class="ref-vol">40</span>:284–6.</span> [<a href="/pubmed/20446223" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20446223</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.g_rg.2007.1139">G&#x000f6;rg M, Wilck W, Granitzny B, Suerken A, Lukacs Z, Ding X, Schulte-Markwort M, Kohlsch&#x000fc;tter A. Stabilization of juvenile metachromatic leukodystrophy after bone marrow transplantation: a 13-year follow-up. <span><span class="ref-journal">J Child Neurol. </span>2007;<span class="ref-vol">22</span>:1139–42.</span> [<a href="/pubmed/17890417" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17890417</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.gort.1999.240">Gort L, Coll MJ, Chabas A. Identification of 12 novel mutations and two new polymorphisms in the arylsulfatase A gene: haplotype and genotype-phenotype correlation studies in Spanish metachromatic leukodystrophy patients. <span><span class="ref-journal">Hum Mutat. </span>1999;<span class="ref-vol">14</span>:240–8.</span> [<a href="/pubmed/10477432" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10477432</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.groeschel.2011.1095">Groeschel S, Kehrer C, Engel C. I Dali C, Bley A, Steinfeld R, Grodd W, Kr&#x000e4;geloh-Mann I. Metachromatic leukodystrophy: natural course of cerebral MRI changes in relation to clinical course. <span><span class="ref-journal">J Inherit Metab Dis. </span>2011;<span class="ref-vol">34</span>:1095–102.</span> [<a href="/pubmed/21698385" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21698385</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.groeschel.2016.1133">Groeschel S, Kuhl JS, Bley AE, Kehrer C, Weschke B, Doring M, Muller I. Long-term outcome of allogeneic hematopoietic stem cell transplantation in patients with juvenile metachromatic leukodystrophy compared with nontransplanted control patients. <span><span class="ref-journal">JAMA Neurol. </span>2016;<span class="ref-vol">73</span>:1133–40.</span> [<a href="/pubmed/27400410" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27400410</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.grossi.2008.e220">Grossi S, Regis S, Rosano C, Corsolini F, Uziel G, Sessa M, Di Rocco M, Parenti G, Deodato F, Leuzzi V, Biancheri R, Filocamo M. Molecular analysis of ARSA and PSAP genes in twenty-one Italian patients with metachromatic leukodystrophy: identification and functional characterization of 11 novel ARSA alleles. <span><span class="ref-journal">Human Mutation. </span>2008;<span class="ref-vol">29</span>:E220–30.</span> [<a href="/pubmed/18693274" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18693274</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.harvey.1998.1215">Harvey JS, Carey WF, Morris CP. Importance of the glycosylation and polyadenylation variants in metachromatic leukodystrophy pseudodeficiency phenotype. <span><span class="ref-journal">Hum Mol Genet. </span>1998;<span class="ref-vol">7</span>:1215–9.</span> [<a href="/pubmed/9668161" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9668161</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.hironaka.2015.13104">Hironaka K, Yamazaki Y, Hirai Y, Yamamoto M, Miyake N, Miyake K, Shimada T. Enzyme replacement in the csf to treat metachromatic leukodystrophy in mouse model using single intracerebroventricular injection of self-complementary aav1 vector. <span><span class="ref-journal">Sci Rep. </span>2015;<span class="ref-vol">5</span>:13104.</span> [<a href="/pmc/articles/PMC4539541/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4539541</span></a>] [<a href="/pubmed/26283284" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26283284</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.kehrer.2011a.850">Kehrer C, Blumenstock G, Gieselmann V, Kr&#x000e4;geloh-Mann I., German LEUKONET.  The natural course of gross motor deterioration in metachromatic leukodystrophy. <span><span class="ref-journal">Dev Med Child Neurol. </span>2011a;<span class="ref-vol">53</span>:850–5.</span> [<a href="/pubmed/21707604" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21707604</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.kehrer.2011b.156">Kehrer C, Blumenstock G, Raabe C, Kr&#x000e4;geloh-Mann I. Development and reliability of a classification system for gross motor function in children with metachromatic leucodystrophy. <span><span class="ref-journal">Dev Med Child Neurol. </span>2011b;<span class="ref-vol">53</span>:156–60.</span> [<a href="/pubmed/21087233" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21087233</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.kr_gelohmann.2013.369">Kr&#x000e4;geloh-Mann I, Groeschel S, Kehrer C, Opherk K, N&#x000e4;gele T, Handgretinger R, M&#x000fc;ller I. Juvenile metachromatic leukodystrophy 10 years post transplant compared with a non-transplanted cohort. <span><span class="ref-journal">Bone Marrow Transplant. </span>2013;<span class="ref-vol">48</span>:369–75.</span> [<a href="/pubmed/22941383" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22941383</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.kurosawa.1998.781">Kurosawa K, Ida H, Eto Y. Prevalence of arylsulphatase A mutations in 11 Japanese patients with metachromatic leukodystrophy: identification of two novel mutations. <span><span class="ref-journal">J Inherit Metab Dis. </span>1998;<span class="ref-vol">21</span>:781–2.</span> [<a href="/pubmed/9819708" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9819708</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.lugowska.2010.394">Lugowska A, P&#x00142;oski R, W&#x00142;odarski P, Tylki-Szyma&#x00144;ska A. Molecular bases of metachromatic leukodystrophy in polish patients. <span><span class="ref-journal">J Hum Genet. </span>2010;<span class="ref-vol">55</span>:394–6.</span> [<a href="/pubmed/20339381" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20339381</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF._ugowska.2005a.353">&#x00141;ugowska A, Amaral O, Berger J, Berna L, Bosshard NU, Chabas A, Fensom A, Gieselmann V, Gorovenko NG, Lissens W, Mansson JE, Marcao A, Michelakakis H, Bernheimer H, Ol'khovych NV, Regis S, Sinke R, Tylki-Szymanska A, Czartoryska B. Mutations c.459+1G&#x0003e;A and p.P426L in the ARSA gene: prevalence in metachromatic leukodystrophy patients from European countries. <span><span class="ref-journal">Mol Genet Metab. </span>2005a;<span class="ref-vol">86</span>:353–9.</span> [<a href="/pubmed/16140556" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16140556</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF._ugowska.2005b.48">&#x00141;ugowska A, Berger J, Tylki-Szyma&#x00144;ska A, L&#x000f6;schl B, Molzer B, Zobel M, Czartoryska B. Molecular and phenotypic characteristics of metachromatic leukodystrophy patients from Poland. <span><span class="ref-journal">Clin Genet. </span>2005b;<span class="ref-vol">68</span>:48–54.</span> [<a href="/pubmed/15952986" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15952986</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF._ugowska.2011.e20218">&#x00141;ugowska A, Poni&#x00144;ska J, Krajewski P, Broda G, P&#x00142;oski R. Population carrier rates of pathogenic ARSA gene mutations: is metachromatic leukodystrophy underdiagnosed? <span><span class="ref-journal">PLoS One. </span>2011;<span class="ref-vol">6</span>:e20218.</span> [<a href="/pmc/articles/PMC3112151/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3112151</span></a>] [<a href="/pubmed/21695197" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21695197</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.lukatela.1998.3654">Lukatela G, Krauss N, Theis K, Selmer T, Gieselmann V, von Figura K, Saenger W. Crystal structure of human arylsulfatase A: the aldehyde function and the metal ion at the active site suggest a novel mechanism for sulfate ester hydrolysis. <span><span class="ref-journal">Biochemistry. </span>1998;<span class="ref-vol">37</span>:3654–64.</span> [<a href="/pubmed/9521684" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9521684</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.mahmood.2010.572">Mahmood A, Berry J, Wenger DA, Escolar M, Sobeih M, Raymond G, Eichler FS. Metachromatic leukodystrophy: A case of triplets with the late infantile variant and a systematic review of the literature. <span><span class="ref-journal">J Child Neurol. </span>2010;<span class="ref-vol">25</span>:572–80.</span> [<a href="/pmc/articles/PMC4301611/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4301611</span></a>] [<a href="/pubmed/20038527" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20038527</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.marc_o.1999.337">Marc&#x000e3;o A, Amaral O, Pinto E, Pinto R, S&#x000e1; Miranda MC. Metachromatic leucodystrophy in Portugal-finding of four new molecular lesions: C300F, P425T, g.1190-1191insC, and g.2408delC. Mutations in brief no. 232. Online. <span><span class="ref-journal">Hum Mutat. </span>1999;<span class="ref-vol">13</span>:337–8.</span> [<a href="/pubmed/10220151" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10220151</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.martin.2013.616">Martin HR, Poe MD, Provenzale JM, Kurtzberg J, Mendizabal A, Escolar ML. Neurodevelopmental outcomes of umbilical cord blood transplantation in metachromatic leukodystrophy. <span><span class="ref-journal">Biol Blood Marrow Transplant. </span>2013;<span class="ref-vol">19</span>:616–24.</span> [<a href="/pubmed/23348427" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23348427</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.martino.2005.243">Martino S, Consiglio A, Cavalieri C, Tiribuzi R, Costanzi E, Severini GM, Emiliani C, Bordignon C, Orlacchio A. Expression and purification of a human, soluble Arylsulfatase A for Metachromatic Leukodystrophy enzyme replacement therapy. <span><span class="ref-journal">J Biotechnol. </span>2005;<span class="ref-vol">117</span>:243–51.</span> [<a href="/pubmed/15862354" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15862354</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.mattioli.2007.64">Mattioli C, Gemma M, Baldoli C, Sessa M, Albertin A, Beretta L. Sedation for children with metachromatic leukodystrophy undergoing MRI. <span><span class="ref-journal">Paediatr Anaesth. </span>2007;<span class="ref-vol">17</span>:64–9.</span> [<a href="/pubmed/17184435" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17184435</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.matzner.2005.1139">Matzner U, Herbst E, Hedayati KK, Lullmann-Rauch R, Wessig C, Schroder S, Eistrup C, Moller C, Fogh J, Gieselmann V. Enzyme replacement improves nervous system pathology and function in a mouse model for metachromatic leukodystrophy. <span><span class="ref-journal">Hum Mol Genet. </span>2005;<span class="ref-vol">14</span>:1139–52.</span> [<a href="/pubmed/15772092" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15772092</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.miyake.2014.427">Miyake N, Miyake K, Asakawa N, Yamamoto M, Shimada T. Long-term correction of biochemical and neurological abnormalities in mld mice model by neonatal systemic injection of an aav serotype 9 vector. <span><span class="ref-journal">Gene Ther. </span>2014;<span class="ref-vol">21</span>:427–33.</span> [<a href="/pubmed/24572788" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24572788</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.morana.2009.291">Morana G, Biancheri R, Dirocco M, Filocamo M, Marazzi MG, Pessagno A, Rossi A. Enhancing cranial nerves and cauda equina: an emerging magnetic resonance imaging pattern in metachromatic leukodystrophy and krabbe disease. <span><span class="ref-journal">Neuropediatrics. </span>2009;<span class="ref-vol">40</span>:291–4.</span> [<a href="/pubmed/20446225" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20446225</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.niida.2012.687">Niida Y, Kuroda M, Mitani Y, Yokoi A, Ozaki M. Paternal uniparental isodisomy of chromosome 22 in a patient with metachromatic leukodystrophy. <span><span class="ref-journal">J Hum Genet. </span>2012;<span class="ref-vol">57</span>:687–90.</span> [<a href="/pubmed/22854541" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22854541</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.olkhovich.2003.360">Olkhovich NV, Takamura N, Pichkur NA, Gorovenko NG, Aoyagi K, Yamashita S. Novel mutations in arylsulfatase A gene in three Ukranian families with metachromatic leukodystrophy. <span><span class="ref-journal">Mol Genet Metab. </span>2003;<span class="ref-vol">80</span>:360–3.</span> [<a href="/pubmed/14680985" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14680985</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.peiffer.1959.386">Peiffer J. On metachromatic leukodystrophy (Scholz type). <span><span class="ref-journal">Arch Psychiatr Nervenkr Z Gesamte Neurol Psychiatr. </span>1959;<span class="ref-vol">199</span>:386–416.</span> [<a href="/pubmed/14431398" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14431398</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.pierson.2008.583">Pierson TM, Bonnemann CG, Finkel RS, Bunin N, Tennekoon GI. Umbilical cord blood transplantation for juvenile metachromatic leukodystrophy. <span><span class="ref-journal">Ann Neurol. </span>2008;<span class="ref-vol">64</span>:583–7.</span> [<a href="/pmc/articles/PMC2605197/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2605197</span></a>] [<a href="/pubmed/19067349" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19067349</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.poeppel.2005.1179">Poeppel P, Habetha M, Marcao A, Bussow H, Berna L, Gieselmann V. Missense mutations as a cause of metachromatic leukodystrophy. Degradation of arylsulfatase A in the endoplasmic reticulum. <span><span class="ref-journal">FEBS J. </span>2005;<span class="ref-vol">272</span>:1179–88.</span> [<a href="/pubmed/15720392" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15720392</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.polten.1991.18">Polten A, Fluharty AL, Fluharty CB, Kappler J, von Figura K, Gieselmann V. Molecular basis of different forms of metachromatic leukodystrophy. <span><span class="ref-journal">N Engl J Med. </span>1991;<span class="ref-vol">324</span>:18–22.</span> [<a href="/pubmed/1670590" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1670590</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.rauschka.2006.859">Rauschka H, Colsch B, Baumann N, Wevers R, Schmidbauer M, Krammer M, Turpin JC, Lefevre M, Olivier C, Tardieu S, Krivit W, Moser H, Moser A, Gieselmann V, Zalc B, Cox T, Reuner U, Tylki-Szymanska A, Aboul-Enein F, LeGuern E, Bernheimer H, Berger J. Late-onset metachromatic leukodystrophy: genotype strongly influences phenotype. <span><span class="ref-journal">Neurology. </span>2006;<span class="ref-vol">67</span>:859–63.</span> [<a href="/pubmed/16966551" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16966551</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.regis.2002.351">Regis S, Corsolini F, Stroppiano M, Cusano R, Filocamo M. Contribution of arylsulfatase A mutations located on the same allele to enzyme activity reduction and metachromatic leukodystrophy severity. <span><span class="ref-journal">Hum Genet. </span>2002;<span class="ref-vol">110</span>:351–5.</span> [<a href="/pubmed/11941485" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11941485</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.regis.2006.150">Regis S, Lualdi S, Biffi A, Sessa M, Corsolini F, Parenti G, Filocamo M. Somatic intragenic recombination of the arylsulfatase a gene in a metachromatic leukodystrophy patient. <span><span class="ref-journal">Mol Genet Metab. </span>2006;<span class="ref-vol">89</span>:150–5.</span> [<a href="/pubmed/16782379" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16782379</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.rip.1998.29">Rip JW, Gordon BA. A simple spectrophotometric enzyme assay with absolute specificity for arylsulfatase A. <span><span class="ref-journal">Clin Biochem. </span>1998;<span class="ref-vol">31</span>:29–31.</span> [<a href="/pubmed/9559221" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9559221</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.sessa.2016.476">Sessa M, Lorioli L, Fumagalli F, Acquati S, Redaelli D, Baldoli C, Biffi A. Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: An ad-hoc analysis of a non-randomised, open-label, phase 1/2 trial. <span><span class="ref-journal">Lancet. </span>2016;<span class="ref-vol">388</span>:476–87.</span> [<a href="/pubmed/27289174" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27289174</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.shukla.2011.38">Shukla P, Vasisht S, Srivastava R, Gupta N, Ghosh M, Kumar M, Sharma R, Gupta AK, Kaur P, Kamate M, Gulati S, Kalra V, Phadke S, Singhi P, Dherai AJ, Kabra M. Molecular and structural analysis of metachromatic leukodystrophy patients in Indian population. <span><span class="ref-journal">J Neurol Sci. </span>2011;<span class="ref-vol">301</span>:38–45.</span> [<a href="/pubmed/21167507" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21167507</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.singh.2009.380">Singh RK, Leshner RT, Kadom N, Vanderver AL. Isolated cranial nerve enhancement in metachromatic leukodystrophy. <span><span class="ref-journal">Pediatr Neurol. </span>2009;<span class="ref-vol">40</span>:380–2.</span> [<a href="/pmc/articles/PMC2705062/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2705062</span></a>] [<a href="/pubmed/19380076" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19380076</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.solders.2014.1046">Solders M, Martin DA, Andersson C, Remberger M, Andersson T, Ringden O, Solders G. Hematopoietic sct: A useful treatment for late metachromatic leukodystrophy. <span><span class="ref-journal">Bone Marrow Transplant. </span>2014;<span class="ref-vol">49</span>:1046–51.</span> [<a href="/pubmed/24797185" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24797185</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.spacil.2016.279">Spacil Z, Babu Kumar A, Liao HC, Auray-Blais C, Stark S, Suhr TR, Gelb MH. Sulfatide analysis by mass spectrometry for screening of metachromatic leukodystrophy in dried blood and urine samples. <span><span class="ref-journal">Clin Chem. </span>2016;<span class="ref-vol">62</span>:279–86.</span> [<a href="/pmc/articles/PMC4737087/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4737087</span></a>] [<a href="/pubmed/26585924" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26585924</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.stein.2015.1160">Stein A, Stroobants S, Gieselmann V, D'Hooge R, Matzner U. Anti-inflammatory therapy with simvastatin improves neuroinflammation and cns function in a mouse model of metachromatic leukodystrophy. <span><span class="ref-journal">Mol Ther. </span>2015;<span class="ref-vol">23</span>:1160–8.</span> [<a href="/pmc/articles/PMC4817791/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4817791</span></a>] [<a href="/pubmed/25896249" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25896249</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.tsuda.1996.400">Tsuda T, Hasegawa Y, Eto Y. Two novel mutations in a japanese patient with the late-infantile form of metachromatic leukodystrophy. <span><span class="ref-journal">Brain Dev. </span>1996;<span class="ref-vol">18</span>:400–3.</span> [<a href="/pubmed/8891236" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8891236</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.vagedes.2002.3066">Vagedes P, Saenger W, Knapp EW. Driving forces of protein association: the dimer-octamer equilibrium in arylsulfatase A. <span><span class="ref-journal">Biophys J. </span>2002;<span class="ref-vol">83</span>:3066–78.</span> [<a href="/pmc/articles/PMC1302386/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1302386</span></a>] [<a href="/pubmed/12496078" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12496078</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.van_rappard.2016a.3098">van Rappard DF, Boelens JJ, van Egmond ME, Kuball J, van Hasselt PM, Oostrom KJ, Wolf NI. Efficacy of hematopoietic cell transplantation in metachromatic leukodystrophy: The Dutch experience. <span><span class="ref-journal">Blood. </span>2016a;<span class="ref-vol">127</span>:3098–101.</span> [<a href="/pubmed/27118454" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27118454</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.van_rappard.2016b.103">van Rappard DF, Bugiani M, Boelens JJ, van der Steeg AF, Daams F, de Meij TG, Wolf NI. Gallbladder and the risk of polyps and carcinoma in metachromatic leukodystrophy. <span><span class="ref-journal">Neurology. </span>2016b;<span class="ref-vol">87</span>:103–11.</span> [<a href="/pubmed/27261095" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27261095</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.von_b_low.2002.9455">von B&#x000fc;low R, Schmidt B, Dierks T, Schwabauer N, Schilling K, Weber E, Us&#x000f3;n I, von Figura K. Defective oligomerization of arylsulfatase a as a cause of its instability in lysosomes and metachromatic leukodystrophy. <span><span class="ref-journal">J Biol Chem. </span>2002;<span class="ref-vol">277</span>:9455–61.</span> [<a href="/pubmed/11777924" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11777924</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.von_figura.2001">Von Figura K, Gieselmann V, Jacken J. Metachromatic leukodystrophy. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. <em>The Metabolic and Molecular Bases of Inherited Disease.</em> New York, NY: McGraw-Hill; 2001:3695-724.</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.wang.2007.397">Wang J, Zhang W, Pan H, Bao X, Wu Y, Wu X, Jiang Y. ARSA gene mutations in five Chinese metachromatic leukodystrophy patients. <span><span class="ref-journal">Pediatr Neurol. </span>2007;<span class="ref-vol">36</span>:397–401.</span> [<a href="/pubmed/17560502" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17560502</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.wang.2011.457">Wang RY, Bodamer OA, Watson MS, Wilcox WR, et al.  Lysosomal storage diseases: diagnostic confirmation and management of presymptomatic individuals. <span><span class="ref-journal">Genet Med. </span>2011;<span class="ref-vol">13</span>:457–84.</span> [<a href="/pubmed/21502868" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21502868</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.yavuz.2011.117">Yavuz H, Yuksekkaya HA. Intestinal involvement in metachromatic leukodystrophy. <span><span class="ref-journal">J Child Neurol. </span>2011;<span class="ref-vol">26</span>:117–20.</span> [<a href="/pubmed/21212458" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21212458</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mld.REF.zlotogora.1995.137">Zlotogora J, Bach G, Bosenberg C, Barak Y, von Figura K, Gieselmann V. Molecular basis of late infantile metachromatic leukodystrophy in the Habbanite Jews. <span><span class="ref-journal">Hum Mutat. </span>1995;<span class="ref-vol">5</span>:137–43.</span> [<a href="/pubmed/7749412" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7749412</span></a>]</div></li></ul></div></div><div id="mld.Chapter_Notes"><h2 id="_mld_Chapter_Notes_">Chapter Notes</h2><div id="mld.Author_History"><h3>Author History</h3><p>Arvan L Fluharty, PhD; University of California, Los Angeles (2006-2017)<br />Natalia Gomez-Ospina, MD, PhD (2017-present)</p></div><div id="mld.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>14 December 2017 (sw) Comprehensive update posted live</div></li><li class="half_rhythm"><div>6 February 2014 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>25 August 2011 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>23 September 2008 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>30 May 2006 (me) Review posted live</div></li><li class="half_rhythm"><div>15 November 2004 (mf) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1130</span><span class="label">PMID: <a href="/pubmed/20301309" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301309</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/arts/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/as-def/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1130&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1130/?report=reader">PubReader</a></li><li><a href="/books/NBK1130/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1130" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1130" style="display:none" title="Cite this Page"><div class="bk_tt">Gomez-Ospina N. Arylsulfatase A Deficiency. 2006 May 30 [Updated 2017 Dec 14]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1130/pdf/Bookshelf_NBK1130.pdf">PDF version of this page</a> (533K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#mld.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#mld.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#mld.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#mld.Genetically_Related_Allelic_Disorder" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#mld.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#mld.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#mld.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#mld.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#mld.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#mld.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#mld.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=410[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">ARSA</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Variations in ClinVar</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=NBK1130+AND+genereviews[submitter]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Variations from this GeneReview in ClinVar</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1472020" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1472020" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1472020" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1472020" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301416" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Krabbe Disease</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Krabbe Disease<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Orsini JJ, Escolar ML, Wasserstein MP, Caggana M. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301601" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Neuronal Ceroid-Lipofuscinoses</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Neuronal Ceroid-Lipofuscinoses<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Mole SE, Williams RE. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301718" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">PLA2G6</i>-Associated Neurodegeneration</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">PLA2G6</i>-Associated Neurodegeneration<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Gregory A, Kurian MA, Maher ER, Hogarth P, Hayflick SJ. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24501781" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Leukodystrophy Overview</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Leukodystrophy Overview<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Vanderver A, Tonduti D, Schiffmann R, Schmidt J, van der Knaap MS. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24156116" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">GLB1-</i>Related Disorders</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">GLB1-</i>Related Disorders<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Regier DS, Tifft CJ. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301309" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301309" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e040c1639a66ee2ba435c29">Arylsulfatase A Deficiency - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Arylsulfatase A Deficiency - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T20:25:42-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal103&amp;ncbi_phid=CE8A3D94E0402D110000000003E60157&amp;ncbi_session=CE8A3D94E040C151_0998SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1130%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1130&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1130/&amp;ncbi_pagename=Arylsulfatase A Deficiency - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8A3D94E040C151_0998SID /projects/books/PBooks@5.22 portal103 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>